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ABSTRACT 
Inositol polyphosphate 4-phosphatases (IP4Ps) are lipid phosphatases that remove the 
4-position phosphate from the lipid second messenger phosphatidylinositol 3,4-bis-phosphate 
converting it to phosphatidylinositol 3-phosphate. There are 2 families of IP4P's that are 37% 
homologous to each other denoted type I and type II. Previously, several different isoforms 
of both type I and type IIIP4P had been identified. These include the (3-spIiceoforms of both 
type I and II that contained a hydrophobic tail instead of a hydrophilic tail and a novel 
deletion spliceoform found in brain tissue that is approximately lkDa smaller than type la 
called type I0C2.1 have identified a novel splice variant of type IIP4P. IP4P type I0C3 is an 
1 lOkDa splice variant of type I IP4P's that contains an additional 40 amino acids creating a 
PEST region. The presence of the additional PEST region could play a role in proteolytic 
regulation of type IIP4P. This novel spliceoform is predominantly located in T-cells and in 
other hematopoietic cells. IP4P I0C3 could have specialized roles in immune related functions. 
IP4P are lipid phosphatases, therefore they must be able to get to membranes to have access 
to their substrate. In this dissertation we identify a lipid-binding C2 domain located on the N-
terminal end of both type I and type II IP4Ps. These C2 domains also bind calcium but in the 
presence of calcium lipid binding is decreased. In addition, we identify a short spliceoform of 
type IIIP4P which we denote Stubby. This spliceoform lacks the phosphatase domain and 
consists primarily of a C2 domain. The C2 domain of Stubby is not complete, by sequence 
homology only p-strands 1-6 and all three calcium-binding loops are present. Comparing the 
lipid binding properties of Stubby, type IIP4P C2 domain and the type IIIP4P C2 domain 
revealed different substrate specificity. In a lipid overlay, the IP4P type IC2 domain and 
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Stubby prefer to bind phosphatidylinositol 3,5-bisphosphate whereas the type IIC2 domain 
prefers phosphatidylinositol 3,4,5-tris-phosphate. This suggests that different forms of IP4Ps 
are localized to different places in the cell. 
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Since the discovery that calcium regulation in cells is partially controlled by cleavage 
of phosphatidylinositol 4,5-bisphosphate by the enzyme Phospholipase C, 
phosphatidylinositol signaling has come to the forefront of cell mediated signal transduction. 
The list of proteins that bind or modify phosphatidylinositols has rapidly grown and these 
proteins are now known to be involved in virtually every aspect of the cell from cell growth 
to production of oxidative intermediates during innate immune responses. Some examples of 
proteins involved in phosphatidylinositol signaling include the protein kinase AKT, 
synaptotagmins and p47phox all of which bind phosphatidylinositols. Phosphatidylinositol 
lipid modifying proteins include phosphatidylinositol 3-kinases and phosphatidylinositol 
lipid phosphatases. 
The primary focus of this dissertation is the study of novel lipid binding C2 domain 
found in inositol polyphosphate 4-phosphatases (IP4P). This research provides insight on the 
mechanism of membrane recruitment for IP4P, an important characteristic of IP4P that until 
now has not been characterized. In addition, this research describes two new spliceoforms in 
the IP4P family, type lag and Stubby. Although the precise function of these proteins is not 
clear, the identification of these spliceoforms enhances the diversity of the IP4P family found 
in humans. 
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Dissertation Organization 
The first chapter of the dissertation will provide details of the current body of 
knowledge regarding mechanisms of the production of phosphatidylinositol lipids, their 
modifications and their ability to recruit proteins to the membrane. 
Chapter 2, which has been published in Biochemical and Biophysical Research 
Communications, is the identification of a novel spliceoform of type IIP4P that is primarily 
found in hematopoietic cells. An examination of the genomic sequence of type IIP4P is also 
reported. 
Chapter 3, to be submitted to the journal Biochemistry, involves the identification of a 
novel C2 domain found in type IIP4P. This C2 domain has the currently unique feature of 
having a lipid binding mechanism that is inhibited by increasing amounts of calcium. In 
addition, residues involved in lipid and calcium binding are investigated. 
Chapter 4, to be submitted to the Biochemical Journal, involves the identification of a 
novel alternatively spliced form of type IIIP4P which we denote Stubby. This spliceoform is 
interesting due to the fact that it does not contain the phosphatase domain. In fact it consists 
almost exclusively the N-terminal C2 domain of type IIIP4P. Lipid and calcium binding 
properties of both Stubby and the type IIIP4P C2 domain are characterized. 
Chapter 5 will present general conclusions from this work and where this work can be 
taken to learn more about mechanisms of regulating the IP4P family of proteins. 
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Literature Review 
Introduction to phosphatidylinositol lipid signaling 
Although phosphatidylinositols (Ptdlns) were discovered over 45 years ago, it has 
only been in the last 15 to 20 years that research has shed significant light on their function 
within the cell. Phosphatidylinositols are derived from a D-myo-inositol that is attached to 
diacylglycerol by a phosphodiester linkage at the 1' position (1,2). They are unique 
molecules that can be phosphorylated at the 3',4',5' hydroxyl groups. This makes them very 
versatile in that the addition or subtraction of phosphate groups can lead to the presentation 
of an entirely different motif. This ability leads to signaling specificity being conferred by 
head group configuration. 
In the last 15 years, phosphatidylinositols (Ptdlns) have been shown to be necessary 
for membrane recruitment of many proteins and it is this primary characteristic that makes 
them extremely important regulators of cellular processes (3,4). Protein domains such as PH, 
PX and C2 domains can bind polyphosphorylated phosphatidylinositols providing membrane 
recruitment (5-7). Some examples of proteins containing these domains include the 
PtdIns(3,4)P2 binding PX domain found in p47phox (a protein involved NADPH oxidase 
activation), the PH domain of the protein kinase PDK1 that binds Ptdlns(3,4,5) P3 and the C2 
domain of Rhabphilin3A, which binds PtdIns(4,5)Pz and is involved in synaptic vesicle 
trafficking (7-11). Future research in the field of phosphatidylinositol metabolism should lead 
to important insight on cellular function. 
Phosphoinositide kinases 
Phosphoinositide kinases are lipid kinases that phosphorylate phosphatidylinositol on 
the 3' hydroxyl, the 4' hydroxyl or the 5' hydroxyl on the d-myoinositol ring of 
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phosphatidylinositol. These reactions are performed by phosphatidylinositide 3-kinases 
(Ptdlns 3-kinases), phosphatidylinositol phosphate 4-kinases (PIP 4-kinases), and 
phosphatidylinositol 4-phosphate 5-kinases (1,2,12,13). Since the substrate and the products 
of IP4P are both involved in phosphatidylinositol 3-kinase signaling, Phosphatidylinositide 
3-kinases will primarily be discussed. Other phosphatidylinositol lipid kinases are reviewed 
elsewhere (13,14). 
Phosphatidylinositide 3-kinases 
There are three classes of Ptdlns 3-kinases that are involved in many cellular 
functions (2,15). Class I Ptdlns 3-kinases consists of an 110 kDa catalytic subunit 
(pi 10a,|3,ô,y) and a regulatory subunit (p85a,(3, p55y and plOl) (1,15). Class I Ptdlns 3-
kinases phosphorylate the 3' hydroxyl of Ptdlns, PtdIns(4)P, and PtdIns(4,5)P2 producing the 
lipid second messengers PtdIns(3)P, and PtdIns(3,4)P2 and PtdIns(3,4,5)P^. These kinases 
signal downstream of receptor tyrosine kinases and heterotrimeric G protein receptors. 
Activation is via Src-homology 2 (SH2) domains present on the regulatory subunit to 
phosphorylated tyrosines and by binding of the small G-protein Ras or in the case of class lb 
by the (3y subunits of large heterotrimeric G-proteins (16). All class I Ptdlns 3-kinases also 
contain C2 domains on their catalytic subunit (15,17). 
Class II Ptdlns 3-kinases are relatively unknown. They possess a lipid binding C2 
domain C-terminus that binds lipids by a calcium independent mechanism (18,19). It should 
also be noted that deletion of the C2 domain increased lipid activity of Ptdlns 3-Kinase 
C2P but mutation of the Ptdlns 3-Kinase C2a does not affect its localization (16,17). In 
addition, they contain a PX domain (20). C2 and PX domains will be discussed in more detail 
later. Class II Ptdlns 3-kinases are thought to be involved in insulin dependent skeletal 
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muscle pathways, production of phosphatidylinositols in the nucleus (21). Moreover and in 
Drosophila melanogaster, the Class II homolog acts antagonistically to the EOF receptor 
pathway in wing patterning (22). 
Class III Ptdlns 3-kinases are found in organisms ranging from yeast (Vps34p) to 
humans (pi50) (1). They are involved in regulating vesicular transport processes such as in 
phagocytosis (23). Class III Ptdlns 3-kinase has a preferred substrate of Ptdlns and is thought 
to be the primary producer of PtdIns(3)P in cells (1). 
Phosphoinositide phosphatases 
The removal of phosphate groups from the inositol headgroup to create new second 
messengers is regulated by phosphoinositide polyphosphate phosphatases. These are a large 
family of lipid phosphatases including 3-phosphatases such as PTEN and Myotubularins, 4-
phosphatases and 5-phosphatases such as SHIP (24,25). The tumor suppressor PTEN 
(phosphatase and tensin homolog deleted on chromosome 10) was first identified as a 
putative tyrosine phosphatase that is mutated in human prostate, breast and brain tumors. 
PTEN removes the 3-position phosphate from PtdIns(3,4,5)P^ converting it to PtdIns(4,5)P2. 
Mutations in PTEN give rise to Cowden syndrome, which has the characteristic of increased 
breast and thyroid tumors (24,26,27). PTEN is a member of the protein tyrosine phosphatase 
(PTP) superfamily of enzymes. The primary characteristic of FTP proteins is the presence of 
a conserved active site motif (CX5R) or in PTEN CKAGKGR. The presence of Lys residues 
is positions C+1 and C+4 makes PTEN different from other PTP family members (28). This 
allows for the catalysis of the primary substrate of PTEN PtdIns(3,4,5)P^. PtdIns(3,4,5)P^ is 
produced by Ptdlns 3-kinases and as stated previously is involved in the regulation of 
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numerous cellular activities including cell growth, differentiation and modulation of immune 
functions (1). 
PTEN A mice die before birth with defects in development and regions of increased 
cellular proliferation (26,29). PTEN also is expressed highly in Purkinje cells and antisense 
oligonucleotides that suppressed PTEN levels lead to death of neurons (29). An examination 
of cells that have mutations in PTEN contain elevated protein kinase B (AKT) activity 
leading to increased cellular survival (30-32). Other proteins that are regulated by PTEN 
include p70S6 kinase and Tek homology kinases such as ITK (33,34). AKT, p70S6 kinase 
and ITK are all downstream effectors of Ptdlns 3-kinase signaling and either are activated by 
proteins that can interact with phosphoinositides or interact with phosphoinositides 
themselves. Thus, PTEN is a negative regulator of Ptdlns 3-kinase signaling. 
Myotubularins are also phosphoinositide 3-phosphatases, but they have different lipid 
specificity when compared to PTEN. They will convert PtdIns(3)P and PtdIns(3,5)Pz to 
Ptdlns and PtdIns(5)P respectively, by hydrolyzing the 3-position phosphate (25). 
Myotubularins are a very large family containing 13 members, eight of these members have 
been shown to be active (25). The active site of Myotubularins contains a conserved CX5R 
motif, but instead of the Lys residues found in catalytic site of PTEN they contain Asp 
residues at C+1 and C+4 and a Trp residue at C+3 (35). It is thought that these amino acids 
provide lipid specificity towards their substrates. 
Myotubularins have been implicated in two different genetic diseases. First, is a 
mutation in MTMl that will lead to a X-linked myotubular myopathy, a disease characterized 
by muscle weakness in newborns (36,37). A role for MTMl could be in the regulation of 
myotube formation. The overexpression of inactive MTMl (D278A) leads to a reduced 
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accumulation of PtdIns(5)P suggesting that its primary substrate is PtdIns(3,5)P2 (38). 
PtdIns(5)P has been implicated in osmotic stress responses in mammals and plants (39,40). 
Also, stimulation of EGF recruits MTMl to late endosomes. Overexpression of WT MTMl 
leads to abrogation of the transition from late endosomes to lysosomes (41). 
SHIP (SH2 domain-containing Inositol 5-Phosphatase) contains two primary 
members (SHIPl and SHIP2) and several alternatively spliced isoforms. SHIP family 
members convert PtdIns(3,4,5)P3 to PtdIns(3,4)P2. SHIPl is expressed primarily in 
hematopoietic cells but can also be detected in testis (41-43). To date SHIPl has been linked 
to numerous processes involved in the immune system. SHIPl is a negative regulator of 
myeloid cell development, mast cell activation and B-cell activation (42). It also localizes to 
the phagosomal cup during phagocytosis, which will be discussed later (44). Activation of 
SHIP occurs via phosphorylation of the SH2 domain and membrane recruitment. During B-
cell activation and mast cell degranulation SHIPl is recruited to the FcyRIIB and FceRI 
receptors respectively (45). In neutrophils SHIP is activated downstream of Lyn kinase after 
stimulation of the oxidative burst suggesting an additional function besides initiation of the 
burst. This has been shown to lead to increased apoptosis in neutrophils (46). A knockout 
mouse of SHIPl has been created. These mice die from myeloproliferative disease consistent 
with a function of regulating the development and proliferation of lymphocytes and other 
immune cells (42). 
Inositol polyphosphate 4-phosphatases 
Inositol polyphosphate 4-phosphatases (IP4P) are a family of enzymes that catalyze 
the hydrolysis of the Ptdlns 3-kinase lipid second messenger PtdIns(3,4)P2 to PtdIns(3)P and 
have been implicated in the regulation of phosphatidylinositol 3-kinase lipid second 
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messenger signaling (47). In humans, two different genes encode IP4Ps, type 14-
phosphatases are located on chromosome 2ql 1.2 and type II 4-phosphatases are located on 
chromosome 4q28.1-q31.1 (48). An examination of the amino acid sequences of type I and 
type IIIP4P shows that they are 37% homologous to each other (24). Type I and type II 
IP4P's are alternatively spliced (49). Type I is spliced in two places, the first site of splicing 
is located on the C-terminal tail and leads to the production of either a hydrophilic tail 
denoted type la or a hydrophobic tail denoted type I[3 (49). The second site of alternative 
splicing affects the central region of the protein and leads to a short 104-kDa form (Ia2) or a 
longer 105-kDa form (Ia)(50). To date no activity has been identified for the 1(3 isoforms of 
both type I and type IIIP4P (49). Both type I and type II IP4Ps are magnesium independent 
and IP4P family members contain the conserved CX5R PTP active site motif 
(CKSA/GKDRT). Using Northern blotting type IIP4P has been shown to be located in 
brain>heart =skeletal muscle>spleen>kidneys (50). The current function of type IIIP4P is 
currently unknown. It has a molecular weight of 105 kDa and has been identified by 
Northern blot to be expressed primarily in skeletal muscle>heart»>brain=placenta= 
pancreas>liver> kidney and lung tissue (49). Using lysates of platelets, rat brain, heart, 
skeletal muscle and spleen >95% of IP4P activity can be immunoprecipitated using an 
antibody that recognizes the C-terminus of type IIP4P (50,51). This suggests that th erelative 
abundance of type IIIP4P in these tissues is very low. 
Very little is known about the functional regulation of type IIP4P in cells. In 
platelets, type IIP4P is proteolytically cleaved by calpain proteases after thrombin or calcium 
ionophore stimulation (52). Using EDTA or the calpain inhibitor calpeptin blocks IP4P 
degradation (52). In addition, in platelets the p85 subunit of Ptdlns 3-kinase has been shown 
9 
to interact with type IIP4P in co-immunoprecipitation experiments (47). Also in a GATA I 
transcriptions factor knockout mouse, type IIP4P transcription was found to be decreased 
(53). In a GATA7" megakaryocyte cell line addition of type IIP4P via retroviral transfection 
resulted in decreased lifespan. IP4P also could play a role in cell proliferation, using NIH 
3T3 cells there is a 2.5 fold decrease in proliferation in IP4P overexpressing cells when 
compared to control cells (53). Recently an IP4P"A mouse has been created; this mouse dies 
approximately 21 days after birth. The overall phenotype is failure to thrive with abnormal 
neuronal development, seizures and defects in hematopoietic development (54). Type IIP4P 
has also been implicated in regulation of the NADPH oxidative burst in neutrophils. Using an 
in vitro assay and superoxide production two proteins were identified that could promote the 
formation of superoxide. These proteins were the inositol polyphosphate 5-phosphatase 
SHIPl and IP4P (55). 
In summary, the addition or removal of phosphate groups from 
polyphosphatidylinositols by Ptdlns kinases and phosphatases allows for the production of 
completely new signaling mediators. These signals are then propagated by the ability of 
proteins to associate with membranes in a lipid specific mechanism. IP4P is a lipid 
phosphatase involved in the production of PtdIns(3)P from PtdIns(3,4)P2. This enzymatic 
action terminates signaling downstream of the lipid substrate PtdIns(3,4)P2but potentiates 
lipid signaling downstream of its product PtdIns(3)P (56) 
The targeting of intracellular proteins to membranes plays a major role in cellular 
processes. These processes include vesicular transport, cytoskeletal reorganization and 
receptor mediated signaling (4). Proteins are able to accomplish membrane recruitment 
through a variety of domains that have evolved to provide specific targeting of proteins to 
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their substrates. These domains include Pleckstrin homology (PH), Phox homology (PX), 
FYVE domains (Fabl, YTOB, Vacl and EEAl), and C2 domains. PH, PX, and FYVE 
domains interact with phosphatidylinositol lipids in a calcium independent mechanism 
whereas membrane binding of C2 domains can be regulated by calcium. 
PH domains were first identified in the protein Pleckstrin and function as 
polyphosphatidylinositol binding domains. PH domains consist of approximately 120 amino 
acids and they are frequently found in proteins mediated by Ptdlns 3-kinase signaling. These 
include tyrosine kinases (Bruton's tyrosine kinase), phospholipases (PLC-ô), and Ser/Thr 
kinases (AKT, PDK1) (11). 
PX domains have only recently been characterized. They are frequently found on 
proteins involved in the NADPH oxidative burst (p47phox, p40phox) but can be found in other 
processes such as vesicular sorting in yeast (Vam7p) and (sorting nexin family (SNX) in 
humans (56). They are even located in class II Ptdlns 3-kinases. PX domains consist of 
approximately 130 amino acids and can have lipid specificity for a range of 
phosphoinositides including PtdIns(3)P (p40phox) and PtdIns(3,4)P2 (p47phox) (56) 
FYVE domains are small domains that contain approximately 70 amino acids. FYVE 
domains are found in numerous proteins including human early endosomal antigen 1 (EEAl) 
and the mammalian ortholog of yeast PtdIns(3)P 5-kinase Fabl, (PIK-fyve) (57). Both of 
these proteins are involved in vacuolar or endosomal trafficking. FYVE domains typically 
have lipid specificity for PtdIns(3)P. 
C2 Domains 
A primary finding of this thesis is the identification of a C2 domain located on the N-
terminus of IP4Ps and the characterization of its lipid and calcium binding properties. C2 
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domains were originally identified and characterized as a calcium dependent lipid-binding 
domain located in protein kinase C (58). They consist of approximately 130 amino acids that 
are conserved in a common structure and are the second most common calcium-binding 
domain in the human genome (59-62). The overall structure of C2 domains consists of eight 
(3-strands that form two (3-sheets to create a (3-sandwich (63). Three loops on the upper 
surface and 3 loops on the bottom surface link the eight strands (64). C2 domains are 
typically classified by their structural properties. There are two structural topologies of C2 
domains, topology I and topology II (59,60). A comparison of 109a carbons of the topology 
I C2 domain found in synaptotagmin C2A to the topology II C2 domain found in 
phospholipase C only deviate by a root 
square mean of 1.4A (59). The major 
difference between the two topologies 
is that if the strands/loops are aligned, 
strand one in topology IC2 domains is in 
the same location as strand eight in 
topology II C2 domains (59). 
The (3-strands create the platform for the loops to project from (Figure 1). As seen in 
figure 1, the loops are primarily the site of lipid and calcium interaction (59,65). C2 domains 
can also be classified due to their function. Proteins that contain single C2 domains 
frequently are involved in the modification of lipids. These include phospholipases and the 
Figure 1. C2 domain of phospholipase C delta (65). 
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phosphatidylinositol 3 phosphatase PTEN. Proteins that contain two or more C2 domains are 
frequently involved in vesicular transport such as synaptotagmins (60,66,67). 
When an alignment of C2 domains is examined comparing the calcium-dependent C2 
domains of Synaptotagmin C2A (Syt C2A), cytosolic Phospholipase A2 (cPLA2), 
Phospholipase Cô (PLCôl) and the calcium-independent C2 domain of Protein kinase C 
epsilon (PKCe), the areas in the C2 domain that contain the highest degree of homology are 
located in the (3-strands (59,62,68,69). These residues are primarily hydrophobic residues 
involved in packing of the sandwich. Within the loops connecting the strands differences can 
be seen. These differences frequently involve charged amino acids within the loops and 
determine the ability of C2 domains bind lipids via calcium-dependent or independent 
mechanisms. 
C2 domains can bind lipids in a calcium-dependent or calcium-independent 
mechanism. To date, only a small fraction of proteins known to contain C2 domains have 
been characterized with respect to the ability of their C2 domains to bind lipids. SytC2A, 
PLCôl, Rabphilin3A, Piccolo, and cPLA2 all contain C2 domains that bind lipids in the 
presence of calcium (9,63,70-72). Protein kinase C epsilon (PKCe), and PKCô contain a C2 
domain that binds lipids in a calcium-independent mechanism (64,68,73). 
In Ca2+-dependent C2 domains, Ca2+ is coordinated by amino acid residues located in 
the calcium binding regions (CBR) linking the top of the (3-sheets. Ca2+ coordination is 
frequently by conserved Asp residue side chains and by the backbone carbons of other 
residues located in CBRl and CBR3 (60). In SytC2A, there are five conserved Asp residues 
whereas in PLCôl there are only four (67). Binding of Ca2+ results in a change in the overall 
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charge distribution on the surface of the C2 domain making it more positively charged 
(71,74). This process has often been called an electrostatic switch (75). This allows the C2 
domain to interact with the polar head groups of the membrane in an electrostatic mechanism 
(74). This is especially seen with SytC2A, Rabphilin 3A, Synaptotagmin-like protein 3 
(Slp3), PKCa, and a recently characterized C2 domain found in Piccolo (9,71,76,77). Piccolo 
however, also undergoes a major structural shift with the addition of Ca2+ allowing it to bind 
lipids (63). All of the above C2 domains have been shown to prefer negatively charged lipid 
head groups such as phosphatidylserine and phosphorylated phosphoinositides (9,66,70,78-
80). Increasing the ionic strength in solution eliminates electrostatic interactions of calcium 
dependent C2 domains (68,81). This has been shown for Syt C2A, Piccolo and SLP-3 
(61,63,76,77,82). 
There are however a class of Ca2+-dependent C2 domains that are not sensitive to 
increasing ionic strength. These C2 domains do not bind PS, instead they interact with PC in 
a Ca2+-dependent manner (71,83,84). This class has been characterized by examining the 
ability of cPLA2 to interact with lipids. At 1M NaCl, cPLA2 still interacts with PC vesicles 
indicating that it interacts with PC via hydrophobic residues in its CBR (71). The ability of 
cPLA2 to translocate to the hydrophobic phase has also been demonstrated using Triton X-
114. cPLA2 C2 can be isolated in the detergent phase whereas the SytC2A domain does not 
(71). Mutations in conserved Asp residues within the CBR of cPLA2 abolished its ability to 
translocate to membranes in a calcium-dependent mechanism (85). 
To date the primary property of C2 domains that has been described is their ability to 
bind lipids. Overall most C2 domains in vitro do not show specificity for individual lipids. 
Instead they tend to interact with negatively charged lipids or with neutral lipids in vitro. One 
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good example is the localization via calcium-dependent C2 domain of cPLA2 to the Golgi, 
endoplasmic reticulum or nuclear membranes (85-87). Another is the C2 domain of PKCa. 
PKCa C2 is directed to the plasma membrane shortly after stimulation with ionomycin (86). 
The Syt C2A domain localizes to synaptic vesicles but it should be noted that Synaptotagmin 
I is an integral membrane protein so it does not require its C2 domain for membrane 
interaction. Its C2 domain mediates the overall ability to bind membranes but it is not 
involved in translocation. In experiments using GFP, after stimulation with ionomycin 
SytC2A exhibits a biphasic membrane translocation. First it moves towards the plasma 
membrane to areas rich in Ptdlns (4,5)P2, followed by a rapid movement to the trans-Golgi 
network (85). C2 domain containing proteins also can localize to the nucleus. Double C2 
protein y (Doc2y) and Tac2N are recently characterized C2 domains containing proteins that 
also have a nuclear localization sequence located within CBR3 loops within their C2 
domains. Both of these proteins have been shown to localize to the nucleus (88-90). Future 
studies using GFP tagged C2 domains should provide greater detail on the actual lipid 
substrates of C2 domains and where they localize. 
The ability of Ca2+-independent C2 domains to bind lipids has been described for the 
C2 domains found in PTEN, Ptdlns 3-kinase C2|3 and PKCe (18,64,91). The C2 domain of 
PTEN was originally identified from its crystal structure (91). It does not contain significant 
homology to other known C2 domains such as SytC2A or PKCa. PTEN appears to prefer 
Phosphatidylserine over Phosphatidylcholine, however, no other lipid substrates have been 
tested to date (91). This is also the case for the C2 domain in Ptdlns 3-kinase C2(3 (18). A 
recent report indicates that the synthetic phosphatidylinositol Di-(C8) PtdIns(4,5)P2 activates 
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PTEN in the presence of its substrate PtdIns(3,4,5)P3 (92). It would be interesting to 
determine if the C2 domain in PTEN will interact with PtdIns(4,5)P2. The C2 domain of 
PTEN has been proposed to function in the orientation of the active site towards its substrate 
(93). Positively charged residues located in the CBR regions mediate lipid binding (91). 
Mutation of these residues abrogates the tumor suppressor function of PTEN in U87-MG 
glioblastoma cells (94). As previously stated, class I and class II Ptdlns 3-kinases contain C2 
domains (17,18). These C2 domains are Ca2+-independent and bind PtdSer. Deletion of this 
C2 domain increases the in vitro activity using Ptdlns as a substrate (18). 
The crystal structure of the C2 domain located in PKCe C2 haas been determined. In 
the presence of Mg2+, Mg2+ is shown to be coordinated within the crystal instead of calcium, 
this is an interesting finding, although further verification by in vitro methods is necessary. 
Deletion of polybasic residues located in CBR3 decreases the ability to bind phosphatidic 
acid (68). PKCe only contains two of five conserved Asp residues found in calcium-
dependent C2 domains. Deletion of these residues eliminates lipid binding in calcium-
dependent C2 domains but has no affect on PKCe lipid binding (95). 
In summary, C2 domains present the unique ability to recruit or modify protein lipid 
interactions. This is accomplished by their ability to bind lipids and in the regulation of lipid 
binding by calcium-dependent or independent interactions. Their roles can vary from the 
modulation of synaptic vesicle transport by synaptotagmins, the regulation of phospholipase 
A2 to Golgi vesicles to the orientation of the lipid substrate of PTEN for enhanced enzymatic 
activity. 
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Immune responses involving Ptdlns 3-kinase signaling and IP 4P 
Although IP4P has been linked to many different responses its role in the production 
of superoxide and the oxidative burst is particularly intriguing. In mammals, the NADPH 
oxidase is essential for host defense against microbial pathogens. This is directly evidenced 
by the fact that genetic defects in the oxidase complex result in chronic granulomatous 
disease (CGD)(96-100). Patients with this disease are highly susceptible to infections by 
pathogens such as Staphylococcus Aureus, Burkholderia cepacea and Aspergillus (101). 
These microorganisms frequently cause pneumonia in CGD patients that can be very difficult 
to treat. Another symptom of the disease is the presence of inflammation, which can lead to 
gastric strictures and chronic inflammation in the lungs (7,101). Over time this can also be 
fatal. 
Lipid signaling plays an important role in the production of reactive oxidative 
intermediates (ROI) that are subsequently involved in host defense. Three of the proteins 
involved in superoxide production contain a lipid-binding domain. In p47phox and p40phox 
there is a lipid binding PX domain (7,8). The PX domain of p47phox has been shown to be 
able to bind the substrate of IP4P (PtdIns(3,4)Pz) and the p40phox PX domain can bind the 
product of IP4P (PtdIns(3)P). In addition, Rac2 contains a prenylation site on its C-terminal 
end that allows for the addition of farnesyl groups that can subsequently be used for 
membrane recruitment (102). 
The function of the NADPH oxidase is to produce ROI such as superoxides that are 
microbicidal towards bacterial and fungal pathogens (101,103). These intermediates have 
also been shown to activate proteases that also are involved in destruction of pathogens 
(100). The production of ROT s can also be detrimental. Overproduction of ROI has been 
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linked to ischemic injury found in heart attacks and strokes (104,105). There are five major 
proteins involved in the activated NADPH complex. These include two integral membrane 
proteins, gp91 and p22phox that together form the cytochrome b558 complex (106-108). There 
are also three cytosolic proteins, p47phox, p67phox and the small GTPase Rac2 (101,103). 
Gp91 contains an NADPH binding site, FAD and two non-identical heme groups (108,109). 
p22phox is not stable unless it is co-expressed with gp91, it has been shown to bind 
phosphorylated p47phox upon activation (110,111) (Dinauer personal communication). 
The NADPH oxidase complex is regulated by the Ptdlns-dependent recruitment of 
p47phox, p67phox and p40phox to the complex at the membrane upon receptor binding (103). 
These proteins are held together in a complex by SH3 domain interactions (103,112). Upon 
activation, p47phox is phosphorylated by protein kinase C0 and possibly by AKT and 
translocates to the membrane (111,113-115). Beyond its adaptor function, the use of in vitro 
experiments or systems that overexpress p67phox, ROI's can still be produced (103,107). 
Therefore, p47phox is not necessary for production of ROI's. p67phox however, is thought to be 
involved in the transfer of electrons to NADPH and there is some evidence that p67phox can 
bind NADPH (55,116). The function of p40phox is not understood, it is not however necessary 
for production of the oxidative burst. 
Recent evidence has shed light on the mechanism of NADPH oxidase regulation by 
Rac2. The GTP bound form of Rac2 will interact with p67phox via N-terminal region of 
p67phox binding to Rac2 via its switch region (117). Neutrophils purified from Rac2 A mice 
are deficient in chemotaxis and superoxide production (118). In a transgenic COSphox cell 
system, it has been shown that the level of superoxide production is dependent upon the 
amount of activated Rac that is present in the cell (119). In addition, the activation of Rac2 
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occurs by the guanine nucleotide exchange factor regulated by Ptdlns 3-kinase signaling, P-
Rexl. It is this activation of P-Rexl that stimulates the production of superoxide (120). P-
Rexl is activated by both PtdIns(3,4,5)P3 and by the G (By subunits of large heterotrimeric G 
proteins (120). 
PtdIns(3)P lipids have also been shown to have an essential role stimulation of 
superoxide production. In vitro experiments have shown that addition of PtdIns(3)P to 
neutrophil lysates stimulates superoxide production (55). PtdIns(3)P can be produced from 
type I Ptdlns 3-kinases or it can be produced from the reaction catalyzed by inositol 
polyphosphate 4-phosphatases (1,51). In a cytosolic purification experiment, the lipid 5-
phosphatase SHIP and IP4P were purified by their ability to stimulate superoxide production 
(26,55). This links the lipid substrate of 4-phosphatases to regulation of the oxidative burst. 
Phagocytosis in mature Phagocytes and in Neutrophils 
In mammals, there are two primary cells that are involved in phagocytosis of particles 
greater than 50|iM. These are macrophages and neutrophils (121). Both neutrophils and 
macrophages contain and undergo phagocytosis via Fey receptors and the complement 
receptor 3 (CR3) (44,121,122). The majority of live cell research on phagocytosis has been 
performed using GFP labeled proteins and macrophages. The overall mechanism of 
phagocytosis in neutrophils is unclear due to the inability to manipulate neutrophils. This is 
due to the fact that they are very short lived as primary cells having an average lifespan of 16 
hours. Therefore, phagocytosis via Fey receptors in phagocytes will be the primary focus of 
this review. 
The process of phagocytosis can be broken down into several steps. The first is 
initiation of phagocytosis by Fey receptor activation; this is followed by cytoskeletal 
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reorganization, formation and closure of the phagosomal cup and the maturation of the 
phagosome (123). Purification and proteomic analysis of phagosomes indicates that there are 
at least 140 proteins that are involved in the process of phagocytosis and phagosomal 
maturation (124). 
Upon receptor ligation there is a formation of pseudopods that encircle the particle 
and engulf it in a zipper-like mechanism (125,126). This extension is mediated by the actin 
cytoskeleton (127,128). The actin cytoskeleton plays an important role in phagocytosis and 
phosphatidylinositol lipids play a direct role in the organization of the cytoskeleton. After the 
Fey receptor is bound by IgG, Ptdlns 4-phosphate 5-kinase is activated (128). It produces 
both PtdIns(4)P and PtdIns(4,5)P^. These lipids are able to interact with cytoskeletal proteins 
such as vinculin and talin. Vinculin and talin will subsequently bind actin (128,129). 
Experiments using wortmannin have shown that Ptdlns 3-kinase is not involved in this 
process. Overall this process has been shown in several different experiments. 
Overexpression of Ptdlns 4-phosphate 5-kinase causes an increase in actin polymerization 
(128). Also lipid vesicles consisting of PtdIns(4,5)P^ can recruit actin binding proteins and 
other regulatory factors including the protein N-WASP (130). N-Wasp binds Arp2/3 and the 
small G-protein Cdc42 and is involved in nucleation of actin filaments (131). 
As actin is recruited to the site of phagocytosis there also are type I Ptdlns 3-kinases 
that are activated to produce PtdIns(3)P and Ptdlns(3,4,5) P3 around the phagosomal cup 
(23,44). Phagocytosis is almost completely abrogated by the addition of Ptdlns 3-kinase 
inhibitors wortmannin and LY294002 (132). Recruitment of Ptdlns 3-kinase is by SH2 
domains and tyrosine phosphorylation Syk and by members of the Src family of tyrosine 
kinases (133-135). The lipid phosphatase SHIP is activated immediately prior to closing of 
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the phagosomal cup to convert Ptdlns(3,4,5) P3 to PtdIns(3,4)P2 (44). This process is 
negatively regulated by the lipid 3-phosphatase PTEN. PTEN "A macrophages display a 
phenotype of increased phagocytosis compared to control macrophages (136). 
Maturation of the phagosome has largely been studied using GFP labeled proteins 
that are known to bind during different stages of maturation. This includes the small GTPase 
Rab5a that recruits type III Ptdlns 3-kinase and early endosomal antigen 1 which binds 
PtdIns(3)P produced by type III Ptdlns 3-kinase (123,137). There is some evidence however 
that PtdIns(3)P can be produced before Rab5 is recruited but the mechanism of lipid 
production is not clear (137). If Rab5 recruits type I Ptdlns 3-kinase and Rab5 is not on the 
phagosomal membrane where does the PtdIns(3)P come from? It could come from a yet 
unidentified Ptdlns 3-kinase or perhaps it could be due to the activation of IP4P. As the 
phagosome matures, Rab7 and 9 are recruited as well as lysosomal associated membrane 
protein 1 (LAMP-1) a marker for phagolysosome formation (123). Rab7 is involved in 
regulation of membrane transport from early to late phagosomes (138-140). 
Calcium also plays a role in phagocytosis. As previously stated many of the 
cytoskeletal proteins involved in the formation of actin filaments are also calpain substrates. 
This allows for turnover of actin and movement of the vesicle. Calcium is released via a two-
stage mechanism. Cleavage of PtdIns(4,5)Pz by phospholipase C produces diacylglycerol 
(DAG) and inositol 3,4,5-trisphosphateP3 (IP3). DAG and IP3 then stimulate release of 
calcium and activation of protein kinase C. Recent studies have examined the actual location 
of calcium fluxes during Fey mediated phagocytosis. Upon binding of the receptor there is a 
wave of calcium that is released that travels around the cell. After phagocytosis the wave 
splits into two separate signals, the first travels around the phagosome. The second continues 
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around the cell (122,141). Mutational studies examining the role of the receptor identified 
three residues in the cytoplasmic tail of the receptor (LTL) that when mutated prevented the 
calcium signal from encircling the phagosome. This prevented phagolysosomal fusion 
without influencing the recruitment of the small GTPases Rab5 and Rab7 (138). In a separate 
study, researchers found that calcium controls activation of the NADPH oxidase in 
neutrophils upon (32 integrin mediated phagocytosis (122). 
The role of the oxidative burst in phagosomal killing is controversial. Traditionally, it 
has been assumed that the production of oxidative intermediates is in itself able to kill 
engulfed pathogens. Recently evidence has suggested that production of superoxide is 
involved in the activation of proteases within the phagolysosome (100). This occurs by the 
rise in anionic charged superoxides resulting in the influx of K+ into the endocytic vesicle. It 
is then hypothesized that the rise in ionic strength causes a release of cationic granule 
proteins such as elastases and cathepsin G, these proteases subsequently kill the bacteria 
(100). 
There are some differences in phagosomes when comparing neutrophils to 
macrophages. The process of phagocytosis in neutrophils is not fully understood. This is due 
to the inability to manipulate neutrophils. Neutrophils do produce significantly higher 
amounts of superoxides, they also have granules that contain proteases such as gelatinase and 
alkaline phosphatase. Fusion of these granules appears to be mediated by calcium. It is 
interesting to note that synaptotagmin II associates with specific granules and translocates to 
the phagosome in a calcium dependent mechanism (142). Synaptotagmins contain calcium 
dependent C2 domains and are thought to act as calcium sensors during vesicular fusion. 
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In conclusion, polyphosphatidylinositols are lipid second messengers that mediate 
signal transduction events by their ability to recruit and localize proteins required for many 
cellular processes. These processes include cytoskeletal reorganization, vesicular trafficking 
and production of oxidative intermediates. IP4P are a family of proteins that remove the 4-
position phosphate from the lipid second messenger PtdIns(3,4)P2 to produce a new second 
messenger PtdIns(3)P. These second messengers are able to recruit proteins to the membrane 
by specificity implied by their headgroup conformation. Understanding the role of membrane 
recruitment of IP4P family members will give greater insight into the regulation of processes 
mediated by its substrate and product second messengers. 
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CHAPTER 2. IDENTIFICATION OF A NOVEL 
SPLICEOFORM OF INOSIOTL POLYPHOSPHATE 4-
PHOSPHATASE TYPE I EXPRESSED IN HUMAN 
PLATELETS: GENE STRUCTURE OF HUMAN INOSITOL 
POLYPHOSPHATE 4-PHOSPHATASE 
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Abstract 
Inositol polyphosphate 4-phosphatases (IP4Ps) are enzymes involved in the regulation of 
phosphoinositide 3-kinase (PI3K) signaling. IP4Ps catalyze the hydrolysis of the D-4 position 
phosphoester of the PI3K generated lipid second messenger, phosphatidylinositol 3,4-
bisphosphate. Western blot analysis detected the expression of a novel 110 kDa form of IP4P 
type la in mouse spleen, heart, lung, and uterus. In addition, the 110 kDa form of IP4P type 
la was found to be the major form of this enzyme expressed in human platelets, MEG-01 
megakaryocytes and Jurkat T-cells. RT-PCR analysis of MEG-01 megakaryocytes and Jurkat 
T-cells indicates that the 110-kDa form of IP4P la is derived from an alternatively spliced 
mRNA that encodes an additional internal domain of 40 amino acids not present in the two 
previously described brain IP4P la spliceoforms. The predicted molecular mass of this 
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spliceoform is 109,968 Da, consistent with its apparent molecular mass estimated by Western 
blot analysis. The novel domain is proline rich and contains a PEST sequence characteristic 
of proteins that are rapidly degraded by the calpain family of proteases. Analysis of genomic 
DNA sequence indicates that the IP4P type I gene consists of 25 exons and that this novel 
spliceoform is obtained as a result of an unusual type of differential splicing involving the 
use of an alternative 5'-GU donor splice site during the excision of intron 15. In addition, we 
show that all three known spliceoforms of IP4P la result from alternative splicing involving 
exon 15 and 16 indicating that structural variability in this region of the enzyme may be 
important for its function. 
Introduction 
Phosphoinositide 3-kinases (PI3Ks) phosphorylate the D-3 position of inositol lipids 
to produce the second messengers phosphatidylinositol 3-phosphate (PtdIns(3)P), 
phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)Pi) and phosphatidylinositol 3,4,5-tris-
phosphate (PtdIns(3,4,5)P3). These second messengers are involved in the regulation of 
numerous cellular events including growth, differentiation, vesicular sorting, glucose 
transport and platelet aggregation (1-3). Inositol polyphosphate 4-phosphatases (IP4Ps) are 
enzymes involved in the regulation of PI3K signaling. IP4Ps are Mg2+-independent 
phosphatases that catalyze the hydrolysis of the D-4 position phosphoester of the second 
messenger, PtdIns(3,4)P^ (4, 5). IP4P type I and II are encoded by different genes and have 
37% amino acid identity (6). Both IP4P type I and II mRNAs are alternatively spliced to 
yield transcripts that encode proteins with variable C-terminal domains that are either 
hydrophilic (IP4P la and IP4P lia) or hydrophobic (IP4P 1(3 and EP4P 11(3) (6). IP4P la has 
recently been implicated in the regulation of PI3K signaling in human platelets. IP4P la is 
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inactivated in response to thrombin stimulation in platelets by calpain-dependent proteolysis 
(7). In addition, human platelet IP4P la has been shown to co-immunoprecipitate with PI3K 
suggesting a direct interaction that may be important for the regulation of PI3K in platelets 
(8). 
Here we report that the major form of IP4P la expressed in human platelets is a novel 
110-kDa spliceoform that contains an internal 40 amino acid domain that is not present in the 
previously described brain isoform. This domain contains a PEST sequence, a region rich in 
proline, serine, glutamate/aspartate and threonine residues that is characteristic of proteins 
that are rapidly degraded by the calpain family of proteases (9, 10). Western blot analysis of 
mouse and human tissues and cells indicates that this 110-kDa spliceoform is expressed in a 
tissue-dependent manner. In addition, we describe the genomic structure of the human IP4P 
type I gene and demonstrate that the mRNA encoding the 110-kDa spliceoform results from 
an unusual type of differential splicing involving the use of an alternative 5'-GU donor site 
for the excision of intron 15 that extends this exon by 120 bp. Sequence analysis indicates 
that three spliceoforms of IP4P la result from alternative splicing involving exons 15 and 16. 
This variable internal region of IP4P la spliceoforms may be important for tissue-specific 
function of these enzymes. 
Materials and Methods 
Tissue and cells 
Human brain tissue was obtained from the Harvard Brain Tissue Resource Center. 
Jurkat T-cells clone E-6 (ATCC#TIB-152), Ramos B cells (ATCC CRL-1596), MEG-01 
megakaryocytes (ATCC CRL-2021), NIH 3T3 cells (ATCC CRL-1658) were all purchased 
from the American Type Culture Collection. The NK 3.3 cells were a generous gift from Dr. 
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Joan Cunnick. Human platelets were obtained from normal human donors and were purified 
as described previously (9). 
Cloning ofIP4P type locj cDNA 
Total RNA was isolated from MEG-01 cells and Jurkat T-cells using Trizol reagent 
(Life Technologies, Inc.), and first strand cDNA was synthesized using AMY reverse 
transcriptase (Promega). The antisense IP4P type I specific primer used for the reverse 
transcription was 5 ' -TCACTCATCATGGCCACGCAG-3 '. PGR reactions was performed in 
50 jjl using 2.5 units of Pfu Turbo™ polymerase (Stratagene) and the 125 ng of each 
oligonucleotide. The templates used in these reactions were l(il of first strand cDNA or 1 jug 
of human brain Quick-Clone™ cDNA (Clontech). The oligonucleotides used for PCR were 
5'-CTGACTACATTGCCTCCAAG-3' (sense), and 5'-CGCGCTGTCCTGCATGAGC -3' 
(antisense). PCR reaction mixtures were denatured for 1 minute at 95°C and then cycled 29 
times with a 1 min denaturation step at 95 °C, 1 min annealing step at 58°C, 1.5 min 
extension step at 72°C. Following the PCR cycling, samples were incubated for an additional 
five minute extension at 72°C to fill in any ends. PCR products were blunt end ligated into 
Sma I digested pBluescript SK+ (Stratagene) and sequenced by the Iowa State University 
DNA Sequencing Facility. The IP4P type I0C3 pBluescript SK+ was then subcloned into IP4P 
type la PCDNA3 with S se 8387-1 (Takara Biomedicals) and Sfi-1 (Promega). The cloned 
IP4P type lag PCDNA3 was used for transfections into NIH 3T3 cells. The genomic 
sequence (AC010134) was obtained by a BLAST search of the GenBank database using the 
sequence of IP4P type la. 
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Transfections of IP4P locj 
A 0.4 jig aliquot of each plasmid was transfected into NIH 3T3 cells with 
EFFECTENE (Qiagen). One day after transfection, the cells were washed twice with 
Phosphate Buffered Saline and lysed in 20 mM Tris, 5 mM MgCla, 1 mM EDTA, 1% Triton 
X-100, 1 mM Pefabloc, and ImM leupeptin. The lysates were centrifuged for 10 minutes at 
14,000 rpm and the supernatants collected. 16|il of each supernatant was then diluted with 
4pi of 5x SDS loading buffer and loaded onto a 6% SDS gel, transferred to a nitrocellulose 
membrane, and probed with the polyclonal N-terminal IP4P antibody (5). Detection was 
performed with the SuperSignal West Pico Luminol/Enhancer system (Pierce). 
Results 
Western Blot Analysis of Inositol Polyphosphate4-Phosphatase Type I Expression 
Western blot analysis of mouse tissues using rabbit anti-serum reactive against the C-
terminus of IP4P la detected a novel 110-kDa form of this enzyme expressed in spleen, 
skeletal muscle, lung and uterus (Fig. 1A). This 110-kDa form was shown to be expressed in 
a tissue-dependent manner at varying levels relative to previously described 106- and 102-
kDa spliceoforms designated IP4P la, and IP4P I«2, respectively. Identical results were 
obtained for western blots with rabbit antiserum reactive to the N-terminus of IP4P type I 
confirming that the 110-kDa protein is the novel form of IP4P la (data not shown). In 
addition, Western blot analysis detected the expression of the 110-kDa form of IP4P la in 
human tissues and cultured cells. The 110-kDa form of IP4P I a is the major form expressed 
in human platelets, MEG-01 megakaryocytes, and Jurkat T-cells whereas only the 106-kDa 
enzyme is detected in human brain lysate (Fig. IB). Treatment of Jurkat T-cells lysates with 
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potato acid phosphatase and calf intestine phosphatase had no effect on the electrophoretic 
mobility on the 110-kDa form of the enzyme, indicating that the apparent size difference 
relative to the brain form of the enzyme was not a result of a difference in phosphorylation 
(data not shown). 
Characterization of a Novel Spliceoform ofIP4P Type la 
In order to determine if the 110 kDa form of IP4P la was derived from alternative 
pre-mRNA splicing, RT-PCR analysis was performed using total RNA isolated from MEG-
01 megakaryocytes and Jurkat T-cells. The use of one pair of oligonucleotides resulted in the 
amplification of two products (Fig. 2). The minor product had the predicted 428-bp sequence 
of the previously cloned human brain cDNA encoding the 106 kDa form of the enzyme (5). 
However, the major product had a 548-bp sequence representing a novel alternatively spliced 
mRNA containing a 120-bp insertion encoding a proline-rich internal domain of 40 amino 
acids (Fig. 3A). The predicted molecular mass of this IP4P la spliceoform is 109,968 Da 
consistent with the molecular weight estimated by western analysis. The 548-bp PCR product 
was amplified from both megakaryocytes and Jurkat T-cells RNA but not brain cDNA and 
therefore correlated with the expression of the 110- kDa form of IP4P I a (Figs. IB and 2). 
Western blot analysis of this novel IP4PI a spliceoform transiently expressed in NIH 3T3 
indicates that it has a electrophoretic mobility indistinguishable from that of the 110-kDa 
form of the enzyme expressed in Jurkat T-cells whereas transient expression of the 
previously described 106-kDa spliceoform co-migrated with the major enzyme expressed in 
brain (Fig. 4). These data indicate that the observed 110 kDa enzyme is a novel spliceoform 
of IP4P la. This represents the third spliceoform of IP4P la identified in mammals and is 
therefore designated IP4P las. 
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Analysis of the human genome database indicates that BAC clone RP11-12K18 
derived from human chromosome 2 (GenBank Accession No. AC010134) contains all of the 
known IP4P type I exons. Table 1 and Fig. IB show the intron/exon organization of the IP4P 
type I gene. The open reading frame for this gene is encoded by 25 exons. The start 
methionine and the stop for the C-terminus of IP4P la was found to be 67,559-bp apart. 
Human LP4P type I cDNA untranslated regions (UTRs) have not been well characterized and 
the exons that encode 5' and 3'-UTRs are therefore not defined. Exon 1 contains the ATG 
start codon as well as 103 nucleotides of 5' UTR. Analysis of this genomic sequence 
indicates that the exon 24 and 25 encode the C-termini of IP4P 1(3 and IP4P la spliceoforms, 
respectively. Further analysis shows that the insertion characteristic of IP4P I a3 results from 
the use of an alternative 5'-GU splice site during the excision of intron 15 that extends exon 
15 by 120-bp (Fig. IB). Interestingly, all three of the known IP4P la spliceoforms result 
from alternatively splicing involving exon 15 and 16. IP4P la, transcripts result from the use 
of 5'-GU splice site A during the excision of intron 15 whereas IP4P Iao transcripts are 
formed by splicing exon 15 splice site A to exon 17 thereby skipping exon 16. Inspection of 
exon 15 indicates that between the competing 59-GU splice sites are three repeats spaced 
seven bases apart with the nucleotide sequence CCCCTYCW where Y represents C or T and 
W represents A or T (Fig. 3B). In addition, exon 16 contains the sequence CCCCTCCT with 
this consensus (Fig. 3B). These pyrimidine-rich elements may represent recognition sites for 
splicing factors that regulate the tissue-specific alternative splicing of exon 15 and 16. 
Discussion 
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Inositol polyphosphate 4-phosphatases (IP4Ps) are Mg2+-independent enzymes that 
catalyze the hydrolysis of the D-4 position phosphoester of the PI3K generated lipid second 
messenger, PtdIns(3,4)P2 (4, 5). Two genes that encode IP4Ps have been identified in 
mammals. The IP4P type I gene (INPP4A) and IP4P type II gene (INPP4B) map to 
chromosome 2qll.2 and chromosome 4q28.1-q31.1, respectively (11, 12). IP4P type I and II 
have the conserved sequence CKSAKDRT that contains the CX5R active site consensus 
sequence of Mg2+-independent phosphatases (6, 13). Structural diversity of both type I and II 
IP4Ps results from alternative splicing of pre-mRNAs that results in spliceoforms with 
hydrophilic or hydrophobic C-terminal domains that are designated a and (3-splice variants, 
respectively (6). In addition, two spliceoforms of IP4P la have been identified that differ in 
an internal region of the enzyme. IP4P la, is a 106 kDa form that represents the major form 
of the enzyme expressed in human, rat and mouse brain (5, 14). IP4P la: is a 102 kDa form 
that is a minor species expressed in rat and mouse brain (5). The amino acid sequence of 
IP4P la, and IP4P la? differs in that the proline-rich sequence DCSPPPEESSP encoded by 
human exon 16 is deleted in IP4P la? (5). In this study, we report the identification of a novel 
110 kDa form of IP4P la which we designate IP4P Ia.3. IP4P la; represents the major form 
of IP4P la that is expressed in human platelets, MEG-01 megakaryocytes, and Jurkat T-cells 
(Fig. IB). This enzyme is derived from an alternatively spliced mRNA that encodes a 
proline-rich domain of 40-amino acids in an internal region of the protein not present in the 
previously described spliceoforms. This domain contains two features that may be important 
for the function of this enzyme in human platelets. Previously, it was shown that human 
platelet IP4P la was inactivated in response to thrombin stimulation by calpain-mediated 
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proteolysis (7). Evaluation of this 40-amino acid domain using the computer program PEST-
FIND (9) indicates a strong PEST score of 7.5 for the sequence RPEDPFCDVPSSPCPSTM-
PSTACH. PEST sequences are proline, glutamate/aspartate, serine, threonine rich motifs that 
are common features of proteins that are rapidly degraded by the calpain family of proteases 
(9, 10). The presence of this PEST sequence in IP4P ICC3 may enhance its susceptibility to 
calpain proteolysis, important for its regulation in platelets. In addition, this domain contains 
two PXXP consensus sequences for binding sites of Src homology 3 (SH3) domains that are 
involved in protein complex formation of several signaling proteins (15). Human platelet 
IP4P la was shown previously to form a complex with PI3K (8). This interaction may be a 
result of the binding of these PXXP motifs to the SH3 domain of the p85 regulatory subunit 
of PI3K. 
Analysis of exon/intron organization of the human IP4P type I gene has revealed 
several important features relevant for the alternative splicing of its pre-mRNA. IP4P type I 
gene consists of 25 known exons (Table 1 and Fig. 3). The alternative splicing occurs in two 
regions of the pre-mRNA. Firstly, the variable C-terminal domains characteristic of the a and 
P-spliceoforms result from alternative splicing involving exons 23, 24, and 25 (Fig. 3B). 
IP4P 1(3 transcripts are formed by splicing exon 23 to exon 24 whereas IP4P la transcripts 
are formed by skipping exon 24 and splicing exon 23 to exon 25. Secondly, the variable 
internal domains of the IP4P la spliceoforms result from alternative splicing involving 
exons 15 and 16 (Fig. 3B). Exon 15 contains two competing 5'-donor splice sites that can be 
used in intron excision (Fig. 3B). The use of site A during splicing results in IP4P la, mRNA 
whereas the use of site B extends this exon by 120-bp and results in mRNA encoding the 
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additional 40-amino acid domain characteristic of IP4P lag. IP4P !a^ mRNA results from the 
use of site A during the splicing of exon 15 to exon 17 thereby skipping exon 16. 
The use of alternative 5'-donor splice sites resulting in exons of variable length is 
unusual and has only been reported for a few alternatively spliced pre-mRNAs including 
those encoding the mammalian proteins caldesmon (16) and SWAP (17), and the Drosophila 
fruitless protein (18). The regulation of the alternative splicing of the pre-mRNAs of 
caldesmon and fruitless have been studied in detail and has been shown to involve repetitive 
exonic sequence elements located between the competing 5-GU donor splice sites that 
function as splice enhancers (16, 19). Splice enhancers are short RNA sequences that bind 
members of the SR family of proteins that regulate the choice of splice sites used by the 
spliceosome (20, 21). A diverse group of sequences have been shown to function as splice 
enhancers and both purine and pyrimidine-rich classes of splice enhancers have been 
identified (16, 20). Inspection of the sequence of exon 15 between the competing 5'-donor 
splice sites indicates the presence of three pyrimidine rich elements with the consensus 
sequence CCCCTYCW. In addition, a single element with this consensus sequence occurs in 
exon 16. These sequences may represent splice enhancers important for the tissue-dependent 
splicing of exons 15 and 16 resulting in the expression of the three IP4P la spliceoforms. 
Figure Captions 
Fig. 1: Western blot analysis of the expression of inositol polyphosphate 4-phosphatase type 
la in mouse and human tissues and cells. Lysates were separated on 6% SDS-PAGE and 
then analyzed by Western blotting (A) IP4P la expressed in mouse brain (lane 1), spleen 
(lane 2), heart (lane 3), skeletal muscle (lane 4), lung (lane 5), and uterus (lane 6) was 
detected using rabbit polyclonal antiserum. B. IP4P type la expressed in human brain (lane 
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1), Jurkat T-cells (lane 2), MEG-01 (lane 3), and platelets (lane 4) was detected using rabbit 
polyclonal serum. Each lane represents approximately 10 |ig total protein loaded except for 
the human and mouse brain lanes which represents 1 mg total protein. 
Fig. 2: RT-PCR analysis of alternatively spliced mRNAs of inositol polyphosphate 4-
phosphatase. RT-PCR products generated as described in the materials and methods were 
separated on a 1.5% agarose gel and stained with ethidium bromide. Lane 1 contains DNA 
size markers of 2000, 1200, 800 and 400 bp. Lane 2 contains the PCR products amplified 
from human brain cDNA. The 548-bp and 423-bp RT-PCR products amplified from RNA 
isolated from Jurkat T-cells and MEG-01 are shown in lanes 3 and 4, respectively. 
Fig. 3: Sequence analysis of the novel alternatively spliced RT-PCR product. A. DNA 
sequence and predicted amino acid sequence is shown for the 548-bp RT-PCR product 
amplified from total RNA isolated from MEG-01 and Jurkat T-cells. Bars indicate the 
oligonucleotides used for PCR. The boxes indicate novel amino acid sequence not present in 
the previously described 106 kDa human brain IP4P type la. The asterisk indicates the GT 
representing the 5'-donor site A of exon 15. Dashed lines indicated position of possible slice 
enhancers with the repeated sequence CCCCTYCW where Y represents C or T and W 
represents A or T. B. This schematic represents the exon/intron structure of the IP4P type I 
gene (LNPP4A). Exons are represented by boxes and introns by lines. Exons involved in 
alternative splicing are numbered and connected by angled lines. The exploded diagram 
shows the position of the alternative 5'-GU donor sites involved in excision of intron 15 
labeled A and B. The dark gray box represents the additional 120 bp of exon 15 that encodes 
the domain of 40 amino acids characteristic of the novel spliceoform IP4P lag. 
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Fig. 4: Comparison of the electrophoretic mobility of inositol polyphosphate 4-phosphatase 
type la and lag to that of the endogenous enzyme. Lysates were separated on 6% SDS-
PAGE and then analyzed using rabbit polyclonal serum reactive against the N-terminus of 
IP4P type I. The endogenous enzyme expressed in Jurkat T-cells (lane 1) and human brain 
(lane 2) is compared to IP4P lag (lane 3) and JP4P la, (lane 4) transiently overexpressed in 
NIH 3T3 cells. 
Table 1: Organization of the Human Inositol Polyphosphate 4-Phosphatase Type I Gene 
References 
1. Rameh, L. E., and Cantley, L. C. (1998) J. Biol. Chem. 274, 8347-8350. 
2. Rittenhouse, S. E. (1996) Blood 88,4401-4414. 
3. Lee vers, S. J., Vanhaesebroeck, B., and Waterfield, M. D. (1999) Curr. Opin. Cell 
Biol. 11, 219-225. 
4. Norris, F. A., and Majerus, P. W. (1994) J. Biol. Chem. 269, 8716-8720. 
5. Norris, F. A., Auethavekiat, V., and Majerus, P. W. (1995) J. Biol. Chem. 270, 
16128-16133. 
6. Norris, F. A., Atkins, R. C., and Majerus, P. W. (1997) J. Biol. Chem. 272, 23859-
23864. 
7. Norris, F. A., Atkins, R. C., and Majerus, P. W. (1997) J. Biol. Chem. 272, 10987-
10989. 
8. Munday, A. D., Norris, F. A., Caldwell, K. K., Brown, S., Majerus, P. W., and 
Mitchell, C. A. (1999) Proc. Natl. Acad. Sci. USA 96, 3640-3645. 
9. Rogers, S., Wells, R., and Rechsteiner, M. (1986) Science 234, 364-368. 
10. Rechsteiner, M., and Rogers, S. W. (1996) Trends Biochem. Sci. 21, 267-271. 
46 
11. Joseph, R. E., Walker, J., and Norris, F. A. (1999) Cytogenet. Cell Genet. 
87, 276-277. 
12. LocusLink database at the National Center for Biotechnology website 
http://www.ncbi.nlm.nih.gov. 
13. Zhang, Z.-Y., Wang, Y., Wu, L., Fauman, E. B., Stuckey, J. A., Schubert, H. L., 
Saper, M. A., and Dixon, J. E. (1994) Biochemistry. 33, 15266-15270. 
14. Vyas, P., Norris, F. A., Joseph, R., Majerus, P. W., and Orkin, S. T. (2000) Proc. 
Natl. Acad. Sci. USA 97, 13696-13701. 
15. Cohen, G. B., Ren, R., and Baltimore, D. (1995) Cell 80, 237-248. 
16. Humphrey, M. B., Bryan, J., Cooper, T. A., and Berget, S. M. (1995) Mol. Cell. Biol. 
15, 3979-3988. 
17. Sarkissian, M., Winne, A., and Lafyatis, R. (1996) J. Biol. Chem. 271, 31106-31114. 
18. Ryner, L. C., Goodwin, S. F., Castrillon, D. H., Anand, A., Villella, A., Baker, B. S., 
Hall, J. C., Taylor, B. J., and Wasserman, S. A. (1996) Cell 87, 1079-1089. 
19. Heinrichs, V., Ryner, L. C., and Baker, B. S. (1998) Mol. Cell. Biol. 18,450-458. 
20. Schaal, T., and Maniatis, T. (1999) Mol. Cell. Biol. 19,1705-1719. 
21. Smith, C. W. J., and Valcarcel, J. (2000) Trends Biochem. Sci. 8, 381-388. 
Figures 
Figure 1 
1 
Figure 2 
49 
Figure 3 
A aCAfTACAnWCTCCÀKCCCTCreCCAmCtACTGMM^^ 
Â G $ i q i R A W A « Q K À E E E Q V M L  
R N q q O T l W A R I I I T # R N S R S Ï l  
A0^B(A(TW%CW«GMe*M«GA6MAGW«awa^eMC^ 
Q V O W M E E  E I E K V e L N V e K S l  
Acn«TMn{*G[cnm*KU^ GCATKCWWCr 
( C I I Q H V D K l l % K E R l H ( E C  
CrgtoMTeTmCCCCTGTO^CAGCTCCACCAlXMGtiUyMTMCCCay.CAGCC 
C E 0 V F P C A 4 S C T S K K  G  N  P  G  
àCgCtACT6GATC;*S^:CAWMCCCCTTCTGT(^Tgra:tCTCaCACCAT6CCCCT 
M A Y # I R P E O P f C D V P S & P ( P |  
COK3CA%K(CT^KT(^TK<JkT(CTCàTCTWCCKAa^ 
C  S  p  *  p  S T W e S T A C W  M L T T M 
WGA^LMCCCACGTCMTQGMmMGGmmmrCCTSn^ 
C e S i P G E * 3 E à L Y P l L T T L T  
^T6C5TG6CCATMT<W;T6iKAÂ.mCÂAW<5%CAÏWATTCCÎ<#aCATKA66 
D C V A M N S D K A K  K à M V  F L L M Q  
ACA6C0CG 
O S A  
B te is it n m m 
+4  ^
fie* llMi mm 
w fien 11 is pm| 
l«l taj 
50 
Figure 4 
1 2 3 4 
TABLE 1 
Organization of the Human I nnsllnl Polyphosphate i Fhnsphnkisf! Type I Gene 
Ejran Ixwi briuirtory Bum I rit ran lu Irai bounctary Intron 
na 5' %' hrgth m. 5' 3' length 
I CGC TAC TGGCAG 308 1 8*gWctc tctattc^g 435 
2 CAÂÂ1A GCTTAG 4Z 2 8*=#gbUf attctgtag 1ZB45 
3 citcxa ATTGAG 118 3 Mgttntag 2232 
4 CCAACC GGAACA 128 4 cttixtoig 270 
fi AICTAT ACTAAG 78 S gttggtatt tgntcacag 1653 
i GTcruc GCGAGG 111 6 mltatcmg 914 
7 ATCGTT AATCGG 101 7 gbwaagp Œzctcag 535 
8 TGTTCG AGCCAG 147 8 gtggggpai ctttmg% 4zm 
9 TGTGTG ACAGAG 133 9 gtggglgp, ;iilli:ll.:ig 1955 
10 GGCCCT GATCAG 104 ID glSlKCtatt: gtcattcag 510 
11 ATCAGA GAAACA 10B 11 gtaagtagc ctttago* 2259 
12 TTTTGA GTGTTG 16 1Z gtgggtttt ctttrasig 3813 
13 TACATC GACAAG 183 13 acctgcag iaoo 
14 ACAOGG GAGTGG 218 14 gtg^ktg "»"W8 10GZ l&i' GAGAAA AGAAAG 138 15a gtaacocg gcaagfmag 3533 
15b" GTAACC GCACAC 120 ISh gtgpgtatg 3G53 
16" ATTGCA GCCCAG 32 IG glgccmg 38B7 
17 GTGAAT CAGAOG 173 17 gblgytcc ctrccaag 1001 
18 CTGACC CCTACG 123 18 ratgtetag 875 
18 GCGAGG AAATCG 12 S IB gtag^gt tttctrr^g 2G0 
20 CGACGC CGAGAG 141 2D rrtrrraag ZWD 
21 GTTTGG AGGAT1 97 21 ghwgtatt ctettosig 4145 
22 CCCTGC GCTGAC 112 2Z gkKWt gttgprag 40 B0 
23 ATCTGC GCGCAG 154 23 ttttracag 4431 
.21* CATTGG AAATGA' 177 24 ND^ II tetrcig 
25' TGAGGG ACGTGA^ 129 25 ND^ 
A Itc'i riiil hT'ly spliced mans, 
* Available sequmœ for I he 3 ' UTR does not extend to a recognteabfc spline Jurrtlom and therefore the 3'-tmd tf exons 24 and 25 are 
* lined by their stop codons rather than an In iron boundary. 
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CHAPTER 3. CHARACTERIZATION OF A C2 DOMAIN IN 
TYPE I INOSITOL POLYPHOSPHATE ^ -PHOSPHATASES 
A paper to be submitted to Biochemistry 
Colin T. Shearn and F. A. Norris 
Abstract 
Inositol polyphosphate 4 phosphatases (IP4Ps) are enzymes involved in the regulation of 
phosphoinositide 3-kinase lipid signaling. They catalyze the hydrolysis of the 4-position 
phosphate from phosphatidylinositol 3,4-bisphosphate to phosphatidylinositol 3-phosphate. 
In this paper we have characterized a lipid binding C2 domain located on the N-terminus of 
type I IP4Ps. We show that this C2 domain binds calcium but calcium interactions lead to the 
unique finding that calcium inhibits lipid binding. Mutational analysis of the calcium binding 
loops suggests that Asp 61, 120 and 123 are involved in calcium and lipid binding in vitro 
and Lys 122, R124 are involved in binding lipids in vitro. This paper provides insight into the 
mechanism of membrane interaction of IP4Ps and the role of calcium in regulation of IP4Ps. 
Introduction 
Inositol polyphosphate 4-phosphatases (IP4Ps) are Mg2+-independent phosphatases 
that catalyze the hydrolysis of the D-4 position phosphoester of the second messenger, 
phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)Pi) to produce PtdIns(3)P (1). IP4P la 
have been implicated in the regulation of phosphatidylinositol 3-kinase (PI3K) signaling in 
platelets and in the regulation of the oxidative burst in human neutrophils (2,3). The 
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"Weeble" mouse contains a stop mutation in the IP4P la gene and presents a phenotype of 
neurological dysfunction and death early in life (4). In Caenorhabditis elegans, 
phosphatidylinositol 3-kinase (Ptdlns 3-Kinase) second messengers are involved downstream 
of the insulin like receptor DAF-2. Recent RNAi evidence suggests that IP4Ps are involved 
in Ptdlns 3-Kinase signaling downstream of the DAF-2 receptor (5). Although IP4Ps were 
originally purified from soluble fractions in mouse brains, the possible role of these 
phosphatases in phosphatidylinositol 3-kinase signaling suggests that they must interact with 
membranes to have access to the lipid substrate. The basis of this mechanism is currently not 
known. 
C2 domains are lipid and protein binding domains first discovered in protein kinase C 
that are approximately 130 amino acids in length. They consist of a conserved (3 sandwich 
containing four antiparallel (3 strands that form two (3-sheets. There are two major types of 
C2 domains, topology I and topology II. The overall conformation of the two topologies is 
very similar. Structural studies comparing 109 a-carbons between the two topologies 
however have shown that the overall structures differ by only 1.4Angstroms (6-8). Some 
examples of topology I and topology C2 domains include the Synaptotagmin C2A domain 
and the Phospholipase C8 C2 (PLCô C2) domain. Both of these proteins contain calcium 
dependent C2 domains that interact with lipids and calcium via the calcium binding regions 
(CBR) connecting the (3-strands (9-13). In addition to calcium-dependent C2 domains there 
are C2 domains that bind lipids in a Ca2+-independent manner (14-18). 
Sequence analysis of IP4P la shows the potential of a previously unrecognized C2 
domain located in the N-terminal region of this protein. In this paper we use biochemical 
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techniques to determine the lipid and calcium binding characteristics of the human type I 
IP4P C2 domain. 
Materials and Methods 
Constructs 
All vectors were produced using standard procedures and verified by sequencing. Full 
length IP4P lag was cloned into the baculoviral vector pAcGHLT-A (BD Biosciences 
Pharmingen). Using the Quick Change Site Directed Mutagenesis kit (SDM)(Stratagene) an 
Nde-I site was introduced at the 5' end of pCDNA3 lag. The oligonucleotides were sense 5'-
GCTTGATATCGCTAGCCATATGC ACAGCAAGAGCACAGCCC-3' antisense 5'-
GGGCTGTGCTCTTGCTGTGCATATGGCTAGCGATATCAAGC-3 '. Nde-PCDNA3 Ia3 
was subsequently cut with Nde-I, Not I and ligated into pAcGHLT-A. This vector was 
subsequently used as a template for all other constructs. All other constructs were produced 
using SDM. The initial C2 domain was created by producing a stop codon in pAcGHLT-A-
I0C3 with the following oligos: sense-5'-
GGAGGAGAAGTCAGACTAACGGCCCCCTGTGACC-3', antisense-5 '-GGTCACAGG 
GGGCCGTTAGTCTGACTTCTCCTCC-3 '. All other mutants were created from 
pAcGHLT-A-type IIP4P C2 by SDM using the following oligonucleotides: (R62Q, K63N)-
sense-5-CTGCATACTCCATCGCTAGATCAGAACCCAAATAGTTTTGTTGCG-3% 
antisense-5 ' -CGCA ACAAAACTATTTGGGTTCTGATCTAGCGATGG AGT ATGC AG-3 ', 
(K123N, R125) sense-5'-
CTCTCCGTGTATGATGTCAACGATCAATCTCAGGGAACAATG-3', antisense-
5'CATTGTTCCCTGAGATTGATCGTTGACATCATACACGGAGAG-3 ', (D 121 A, 
D124A) sense-5 ' -CTCTCCGTGTATGCTGTCAAAGCTAGATCTCAGGG-3 ', antisense-
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5'-CCCTGAGATCTAGCTTTGACAGCATACACGGAGAG-3 ', 9D62A), sense-5'-
GCATACTCCATCGCTAGCTCGAAAGCCAAATAG-3', antisense 5'-
CTATTTGGCTTTCGAGCTAGCGATGGAGTATGC-3 '. All constructs were verified by 
sequencing at the Iowa State Sequencing Center. All constructs were transfected into Sf-9 
cells using Effectene transfection reagent (Qiagen) with 0.1 |ig of linearized baculoviral DNA 
(BD-Pharmingen) for every 0.3 |ig of plasmid. The virus was amplified as per 
manufacturer's instructions. 
Reagents 
D (+)-sn-1,2-di-O-hexadecanoylglyceryl, 3-O-phospho linked phosphatidylinositol 
(3,5)-bisphosphate (PtdIns(3,5)P2) was from Echelon Biosciences Inc. Porcine brain L-a-
phosphatidylinositol (4,5)-bisphosphate (PtdIns(4,5)P2), porcine brain L-a-
phosphatidylinositol (4)-phosphate (PtdIns(4)P), L-a-phosphatidylserine, Liver L-a-
phosphatidylinositol (PI), L-a-phosphatidylcholine (PtdCho) and L-a-phosphatidic Acid 
(PA) were from Avanti Polar Lipids, Lissamine Rhodamine B 1,2 dihexadecanoyl sn-
glycero-3-phosphatidylethanolaminetriethylammonium salt (Rh-PE) and Fluo 5N was from 
Molecular Probes. The protease inhibitor cocktail and Fatty acid free BSA were from Sigma. 
Bacterial Protein Extraction Reagent (B-PER) was from Pierce. Glutathione Sepharose 4B 
was from Amersham Biosciences. 
Preparation of lipids 
Fluorescent lipids were prepared as follows: Unless otherwise stated, 20% Ptdlns 
(4,5)Pa, 79% (PC) and 1% Rh-PE were dried using a Savant SCI 10 Speed Vacuum the lipids 
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were subsequently resuspended in lOmM Hepes, lOOmM NaCl pH 7.4, sonicated briefly and 
kept on ice until use. 
Lipid Overlay Assay 
The lipid overlay was performed as previously described using a pre-spotted 
phosphoinositide array (Echelon Biosciences)(19). Briefly the membrane was incubated 
overnight with 5nM of purified GST-IP4P la C2 at 4°C. For detection, the primary antibody 
used was a polyclonal rabbit anti-GST (Molecular Probes) diluted at 1:1000. The secondary 
antibody was Donkey anti-rabbit coupled to horseradish peroxidase (Pierce) at a dilution of 
1:5000 and was detected by Supersignal chemiluminescent system (Pierce). 
Fluorescent Lipid Pull down Assay 
Recombinant Synaptotagmin was purified by glutathione Sepharose chromatography. 
The samples were subsequently mixed at 4°C for 4 hours, washed 3 times in lOmM Hepes, 
1% Triton X-100, 500mM NaCl, 2mM EDTA (pH 7.4), 3 times in lOmM Hepes, 1% Triton 
X-100, lOOmM NaCl, 2mM EDTA (pH 7.4) followed by 3 times in lOmM Hepes, lOOmM 
NaCl, 2mM EDTA (pH 7.4). Proteins were then quantified using a Coomassie blue stained 
10% SDS PAGE gel. All type IIP4P C2 domain proteins were expressed in Sf-9 cells as 
described previously. Flasks were infected for 3 days and subsequently lysed in lOmM 
Hepes, 1% triton, lOOmM NaCl, 2mM EDTA (pH 7.4) plus protease inhibitor cocktail. After 
lysis, lysates were treated as above. For the lipid pull-down assay equal amounts of protein 
beads were incubated in 3OO|0.1 of lipid binding buffer (lOmM Hepes, lOOmM NaCl pH 7.4) 
plus the appropriate lipid. Each lipid mixture was 20% lipid, 79% PC and 1% Rh-PE unless 
otherwise stated. The beads were allowed to shake at 37°C for 1.5 hours. The beads were 
washed 3 times in lipid binding buffer and read on a Titertek fluoroscan II (EFLAB, Finland) 
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microti ter plate reader Excitation was at 544nm; emission was at 584nm. All calcium 
concentrations were determined using Fluo5N and the Max Chelator program 
(http://www.stanford.edu/~cpatton/maxc.html). All graphs were created using Sigma Plot. 
Ca2+ overlay assay 
For each protein 2|ig was spotted on a nitrocellulose membrane pre-wetted with 
Buffer A (50mM Tris, lOOmM NaCl, .ImM EDTA pH 7.4) using a Bio-Dot microfiltration 
apparatus (Biorad). The membrane was incubated for 20 minutes with 70 nM 45Ca2+ 
(Specific Activity 16mCi/mg). Following incubation the membrane was washed briefly twice 
in Buffer A without EDTA, dried, and subjected to autoradiography overnight on Kodak X-
ray film. 
Results 
Sequence analysis of the human type I IP 4P C2 domain 
RPS Blast Database searches with the IP4P la sequence revealed the presence of a 
possible C2 domain with an expect value of 0.25. A comparison of the expect values of the 
known C2 domains of Synaptotagmin C2A (Syt C2A) and Phospholipase C8l (PLCÔ1) 
(expect values of 7x10"40, 5xl0"37 respectively) revealed this expect value to be relatively 
weak. Taking the data from the RPS Blast search a manual alignment was constructed using 
known C2 domain alignments (Figl) (8,20). Based on this homology, we hypothesized that 
there is sufficient sequence similarity between conserved hydrophobic residues located in the 
(3-strands and the overall alignment of conserved residues within the calcium binding regions 
(CBR) to suggest this domain is a C2 domain. The absence of homology with (3-strand 1 in 
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Syt C2A and the presence of homology with |3-strand 8 in PLCÔ1 indicates that the IP4P C2 
domain is topology II. 
Type IIP4P C2 contains some of the Asp residues (D61, D120) located in CBR1 and 
CBR3 that are known to coordinate calcium in other C2 domains such as synaptotagmin (12). 
In addition, Asp 123 is only shifted one position from the Synaptotagmin Asp residue. 
Surrounding these Asp residues are positively charged Lys and Arg residues (R62, K63, 
K123, R125). In Syt C2A and PLCô C2 the positively charged residues are involved in lipid 
binding (9,10). This suggests that type IIP4P C2 might bind lipid and calcium by a similar 
mechanism as typical calcium binding C2 domains. 
Lipid binding properties of type 11P4P C2-like domains 
A lipid-binding assay was performed using a phosphatidylinositol lipid overlay blot 
to characterize the lipid specificity of the type IIP4P C2 domain. A GST fusion of this 
domain interacted with the lipids on the array in the following order of specificity: 
PtdIns(3,5)P2>PtdIns (3,4,5)P)> PtdIns(4,5)P2> PtdIns(3,4)P2> PtdIns(4)P. There was very 
little or no binding observed for PtdIns(3)P, PtdIns(5)P or PI (Fig 2A). In addition, a vesicle 
pull-down assay with Rhodamine labeled vesicles was performed. In this assay, negatively 
charged lipids such as phosphatidic acid, PtdIns(4,5)Pz, PtdIns(3,5)P2 and PtdIns(4)P all 
bound type IIP4P C2 with similar affinity, whereas PC and PI did not detectably bind. In 
separate experiments, PE and PS did not bind (Fig 2b). 
Increasing the mol percent of PtdIns(4)P and PtdIns(4,5)Pi revealed a dose dependent 
lipid binding response (Fig2c). IP4P C2 bound PtdIns(4,5)P2 slightly better than PtdIns(4)P. 
This interaction strongly indicates that type IIP4P C2 domains functions as a lipid-binding 
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domain. Moreover, these data suggest that IP4P la C2 interacts primarily with 
phosphatidylinositols containing primary phosphates and phosphatidic acid. 
Calcium binding of type IIP4P C2 
Many C2 domains such as Syt C2A and PLCô C2 bind calcium however, there are 
calcium-independent C2 domains (9,10,13,14,17). To examine the ability of the type IIP4P 
C2-like domain to bind calcium we performed calcium overlay assays (Figure 3a). A 
nitrocellulose membrane was spotted with type IIP4P C2 with Syt C2A (positive control) 
and GST (negative control). Type IIP4P C2 binding with 45Ca2+ was similar to that of Syt 
C2A. Previous work has shown that the calcium ions are coordinated with conserved Asp 
residues located in the calcium binding regions (7). However, a comparison of these Asp 
residues in type IIP4P C2 to other C2 domains only three of the five are conserved and the 
second Asp found in loop 2 is shifted one position in type IIP4P C2 (See Figure 1). A D61A 
mutation putatively located in CBR1 was subsequently examined in the overlay system. 
Mutation of D61A significantly decreased binding (Fig 3b). This result supports the 
hypothesis that the type IIP4P C2-like domain interacts with calcium by a mechanism 
characteristic of calcium binding C2 domains. 
Effects of calcium on IP 4P type I C2 lipid binding 
In order to evaluate the effect of calcium on lipid binding, we performed a lipid pull­
down in the presence of EDTA or increasing amounts of calcium (Fig 4). Calcium 
concentrations were determined using fluo5N and the Max Chelator program. Surprisingly, 
chelation of calcium using 0.2mM EDTA did not affect lipid binding. Moreover, as calcium 
concentrations were increased, there was a significant decrease in lipid binding. The effects 
of Mg2+ were also examined, increasing concentrations of Mg2+ also decreased lipid binding 
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but binding was only reduced by 40% compared to approximately 80% using Ca2+ (data not 
shown). We also examined the effects of EDTA compared to EGTA and saw no difference in 
lipid binding (data not shown). As a positive control, the Synaptotagmin C2A (Syt C2A) 
domain was also tested. Lipid binding of Syt C2A was strongly inhibited by EDTA and was 
not inhibited by increasing concentrations of consistent with data previously reported (Fig 4 
inset)(21). To our knowledge, this is the first report of an example of a C2 domain inhibited 
by calcium. 
To further test the role of the CBRs in lipid binding, mutations were constructed to 
examine the effects of mutations of the conserved Asp residues located in CBR1 and CBR3 
(Fig 5). In the lipid pull-down assay, the mutant D61A affecting CBR1 (a mutation shown to 
abolish calcium binding) increased lipid binding by approximately 1.5-fold of the WT C2 
domain. A double mutant D121A, D124A located in the predicted CBR3 increased lipid 
binding by approximately 6-fold when compared to wild type. Thus, mutations that abolish 
calcium binding enhance the ability to bind lipid, consistent with a lipid binding mechanism 
where calcium acts in an inhibitory manner. 
Characterization of the mechanism of electrostatic lipid interaction of type I IP 4P C2 
domains 
Previous evidence has shown that C2 domains can interact with lipid bilayers via 
several different mechanisms. These include electrostatic interactions involving basic 
residues, calcium-dependent electrostatic interactions and hydrophobic interactions. (6,21). 
In order to clarify the role of electrostatic interactions, we performed a lipid pull-down assay 
with increasing concentrations NaCl (Figure 6a). Binding of type IIP4P C2 to PtdIns(4,5)Pz 
was decreased by approximately 50+/-18% when the concentration of NaCl increased to 1M. 
61 
This result indicates lipid binding is partially through electrostatic interactions. Other 
calcium-dependent anionic lipid binding C2 domains such as SytC2A and Piccolo exhibit 
primarily electrostatic lipid interactions (21,22). 
In order to further characterize the electrostatic interaction, we examined the role of 
positively charged residues present in the CBRs. Lipid binding properties of the double 
mutant R62N, K63Q (CBRl) and the double mutant K123N, R125Q (CBR3) were examined 
in the presence of increasing mol percent lipids (Fig 6b). The CBRl double mutant had very 
little effect but the CBR3 double mutant showed a decreased ability to bind lipids by 
approximately 50+/-12%. This is in agreement with the 50% decrease seen in figure 6a when 
examining the effects of high salt. This data provides evidence of the role of K123 and R125 
in lipid binding. 
Discussion 
The majority of C2 domains bind lipids in a calcium-dependent mechanism (6). 
However, there are examples of C2 domains such as those found in the lipid phosphatase 
PTEN, Protein kinase Cô (PKCÔ) and PKCe, that do not require calcium to bind lipids 
(14,16-18). In this report we describe a novel calcium binding C2 domain whose lipid 
binding capability is inhibited by increasing concentrations of calcium. 
Analysis of the sequence of the type IIP4P C2 domain suggests that it is a topology II 
C2 domain. Although this domain only contains three out of five Asp residues frequently 
involved in calcium binding, we show that it binds calcium and that calcium binding can be 
abolished by a mutation of Asp residues within the predicted CBRs. This is consistent of a 
mechanism that is similar to other calcium binding C2 domains such as Syt C2A and PLC51 
(6,8). 
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Most C2 domains bind anionic lipids such as PI, PS or zwitterionic lipids such as PC 
(6). In the lipid array, there was a clear preference for PtdIns(3,5)P2. However, there was no 
clear preference between PtdIns(4)P, PtdIns(4,5)P2 and PtdIns(3,5)P2 in the lipid pull-down 
assay. From both assays we conclude that a primary phosphate is necessary for binding. 
The addition of 1M NaCl to the C2A domain of synaptotagmin I and other calcium 
dependent C2 domains has been shown to bind lipids primarily through electrostatic 
interactions as the addition of NaCl has been shown to block lipid binding (6,12,21,22). Lipid 
binding to in the presence 1M NaCl reduced binding by only 50% suggesting that the 
mechanism of lipid interaction is both electrostatic combined with a non-electrostatic 
interactions. To evaluate which amino acids involved in the lipid-binding interface, we 
mutated positively charged amino acids located in CBRl and CBR3. Mutation of these 
residues in calcium-dependent and calcium-independent C2 domains reduces the ability to 
bind lipid (6,14). When we mutated R62N, K63Q (CBRl) and the K123N, R125Q (CBR3) 
lipid binding was only decreased in the CBR3 mutation. This data demonstrates that not all 
of the positively charged residues located in the loops are involved in lipid binding, however, 
positive residues located in CBR3 are important for forming a positively charged electrostatic 
surface for lipid interaction. 
This study shows that lipid binding of the type IIP4P C2 domain does not require 
calcium and surprisingly, calcium is inhibitory. To our knowledge this is the first C2 domain 
with this biochemical property. To gain additional insight concerning the role of calcium 
binding, mutations of Asp residues located within CBRl and CBR3 were constructed. 
Analogous mutations of Asp residues have also been shown to abolish lipid binding in other 
C2 domains (9). When the lipid binding characteristics of D61A (CBRl), and the D121 A, 
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D124A (CBR3) double mutant was examined we see enhanced lipid binding. The single 
mutation D61A in CBRl was experimentally demonstrated to abolish calcium binding, 
however due to poor expression we were unable to evaluate the ability of the double mutant 
to bind calcium. The greatest effect was seen in the CBR3 mutation indicating that it plays a 
major role in lipid interactions consistent with the earlier result of K123N, R125Q also in 
CBR3 exhibiting decreased lipid binding. 
Calcium has been shown to negatively regulate IP4P stability and phosphatase 
activity in the regulation of IP4P has previously been reported (2). This regulation has been is 
performed by the calpain family of calcium-dependent proteases, which cleave type IIP4P 
after platelet stimulation (2,23). Platelets exhibit calcium fluxes upon stimulation activating 
calpains (23). This study suggests that in addition to calpain mediated proteolytic regulation 
of type IIP4P, calcium could also influence the ability of type IIP4P to target to membranes. 
Phosphatidylinositol 3-phosphate (PtdIns(3)P) has been shown to be involved in the 
production of reactive oxidative species by the NADPH complex in neutrophils (3). 
Intracellular calcium release also occurs during these cellular processes. The use of calpain 
inhibitors has been shown to block production of the oxidative burst (24,25,26). During [32 
integrin (CR3) mediated phagocytosis in neutrophils there are calcium fluxes that control the 
sequential closing of the phagosomal cup and production of ROI (26,27). The production of 
PtdIns(3)P by IP4P could be a mechanism of controlling phagosomal cup closure and the 
production of ROI. Regulation of calcium fluxes could be a means of controlling these 
processes by regulating the ability of IP4P to interact with membranes. 
In summary, based on sequence analysis in combination with biochemical analysis 
we have identified a novel C2 domain in the type IIP4P family of proteins. Our results also 
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suggest that this C2 domain has the unique feature of being able to bind calcium but the 
binding of calcium inhibits lipid binding. IP4P la catalyzes the conversion of PtdIns(3,4)P2 
to PtdIns(3)P. In order to accomplish this function access to membranes is necessary. These 
data provides insight on the mechanism of membrane targeting of type IIP4P. 
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Figure Legends 
Fig. 1: Sequence alignment of Synaptotagmin I (Syt C2A), Phospholipase 51 and type IIP4P 
C2. P strands for each topology are shown above and below the sequences. Calcium and lipid 
binding loops (CBRs) are boxed. Residues that interact with calcium or are mutated in type I 
IP4P C2 are shown in bold. 
Fig. 2: Type IIP4P C2 binds to Ptdlns (4,5)P2, Ptdlns (3,5)P2 and Ptdlns (4)P with equal 
specificity. A. Lipid Array using 5nM IP4P C2 domain, lipids were spotted at a range of 
lOOpmol to 1.56pmol. B. Effects of total lipid content on binding of GST type IIP4P C2 
beads compared to GST control. B. Fluorescent lipid pull-down assay demonstrating lipid 
specificity of IP4P C2 domains. 5|ig of GST-IP4P C2 or GST beads was used for each assay, 
lipids were prepared as 79% PC, 20% indicated lipid and 1% Rhodamine labeled PI as 
described in Materials and Methods. A total of 5|ig of GST fusion IP4P C2 was used for each 
assay. C. Effects of Increasing mol percent of PtdIns(4)P (circles), PtdIns(4,5)P2 (squares), 
PtdSer (triangles) and Ptdlns (diamonds) were used in a pull-down assay. The remaining 
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lipid consisted of 1% Rhodamine labeled PE and PC. The data are mean with S.E. using 
three independent experiments. 
Fig. 3: Calcium binding of type IIP4P C2. A. Overlay assay of 45Ca2+ binding of GST-IP4P 
C2 compared to GST and GST-Synaptotagmin C2A. 2|ig of each protein was spotted on a 
nitrocellulose membrane and incubated with 45Ca2+. Following autoradiography exposure, 
the membrane was stained with Ponceau Red. B. Overlay assay of 45Ca2+ binding of GST-
IP4P C2 compared to D61A mutation under the same conditions. 
Fig. 4: Effects of EDTA and calcium on type I LP4P C2 lipid binding. Lipid vesicles were 
prepared as described previously, for each assay five micrograms of protein was used. Type I 
IP4P C2 binding shown in black bars GST binding shown in white. In the inset is GST-
Synaptotagmin as a positive control under the same conditions. The data are mean with S.E. 
using three independent experiments. 
Fig. 5: Mutational analysis of type IIP4P C2 lipid binding. Lipid binding/microgram of 
protein of CBRl and CBR3 Asp mutants. Five micrograms of (IP4P C2-WT, (D61A), 
(D120A, D123A) or GST control beads were used for each assay. PtdCho binding is in gray 
and PtdIns(4)P binding is in black. The data are mean with S.E. using three independent 
experiments. 
Fig. 6: Type IIP4P C2 binding to phospholipid vesicles, effects of NaCl. Effects of NaCl 
concentration on GST IP4P C2 beads lipid binding using 20% PtdIns(4,5)Pz vesicles 
compared to GST beads. Lipid vesicles were prepared as described previously, for each assay 
five micrograms of protein was used. IP4P C2 binding shown in black bars, GST binding 
shown in white. B. Lipid binding/microgram of protein of CBRl and CBR3 mutants. Five 
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micrograms of IP4P C2, (R62N, K63Q), (K123N, R125Q) beads were used for each assay. 
The data are mean with S.E. using three independent experiments. 
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CHAPTER 4. CHARACTERIZATION OF STUBBY: A 
NATURAL C2 DOMAIN CONTAINING SPLICEOFORM OF 
TYPE II INOSITOL POLYPHOSPHATE 4-PHOSPHATASES 
A paper to be submitted to the Biochemical Journal 
Colin T. Shearn, Raji E. Joseph, and F. A. Norris 
Abstract 
Inositol polyphosphate 4 phosphatases (IP4Ps) are enzymes involved in the regulation of 
phosphoinositide 3-kinase lipid signaling. They catalyze the hydrolysis of the 4-position 
phosphate from phosphatidylinositol 3,4-bisphosphate to phosphatidylinositol 3-phosphate. 
In this paper we have identified a novel spliceoform of type IIIP4P which we denote Stubby. 
Stubby is comprised solely of the N-terminal C2 domain of type IIIP4P. In a comparison 
between the type IIC2 domain and Stubby, we show that both proteins will bind calcium but 
that calcium will inhibit the polyphosphatidylinositol lipid binding. We further show that 
Stubby and the type IIIP4P C2 domain have different lipid preferences and that the overall 
mechanism of lipid binding is primarily electrostatic. This paper provides insight into the 
mechanism of membrane interaction of IP4Ps and the role of calcium in regulation of type II 
IP4Ps. 
Introduction 
The family of phosphoinositide 3-kinases (PI3K) phosphorylates the D3 position of 
inositol lipids to produce the lipid second messengers phosphatidylinositol 3-phosphate 
(PtdIns(3)P), phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)Pi), and phosphatidylinositol 
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3,4,5-trisphosphate (PtdIns(3,4,5)P3) (1).These lipids are known to be involved in many 
cellular processes including cell growth, phagocytosis and the production of the NADPH 
oxidative burst (2-4) .Inositol polyphosphate 4-phosphatases (IP4P) are enzymes that are 
involved in the regulation of PI3K signaling in thrombin stimulated platelets and in 
production of oxidative intermediates during the NADPH oxidative burst (5,6) 
IP4Ps are Mg2+-independent enzymes that catalyze the hydrolysis of the D-4 position 
of the lipid second messenger PtdIns(3,4)Pz converting it to PtdIns(3)P (7). The mammalian 
family of IP4Ps consists of two types, type I and type II. Type I and type II are located on 
different chromosomes and have 37% amino acid identity between them (8). Both type I and 
type IIIP4P s are alternatively spliced. Type IIP4P can be spliced at both the C-terminus to 
yield variable C-terminal domains that are either hydrophilic (type la) or hydrophobic (type 
Ip), or it can be spliced within the variable region to yield three different spliceoforms (loci, 
I(%2 and I«3)(9,10). Type II can be alternatively spliced at its C-terminus to yield types Hoc 
and 11(3 which are homologous to type la and 1(3 (10). 
We have recently identified a novel C2 domain on the N-terminus of type IIP4P (11). 
This C2 domain prefers to bind PtdIns(3,5)P^ and in in vitro pull-down assays, calcium 
inhibits its ability to bind lipids (11). C2 domains are domains of approximately 130 amino 
acids that are found in proteins involved in the regulation of vesicular processes and also in 
proteins involved in the modification of lipid second messengers (12). C2 domains contain 8 
(3-strands that form a (3-sandwich. The strands are linked on the top by loops that can bind 
lipid and Ca2+ (13). These regions of C2 domains are also known as Ca2+ binding regions 
(CBR). Currently the function of the loops linking the strands on the other face of C2 
domains is unknown function (13). A possible function for the bottom loops could be in 
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protein/protein interactions. In this paper we report the cloning of an alternatively spliced 
variant of type IIIP4P that consists only of a truncated C2 domain. We compare the lipid and 
calcium binding properties of this unique human protein with the C2 domain that we have 
identified in type IIIP4P. 
Materials and Methods 
Reagents 
D (+)-sn-1,2-di-O-hexadecanoylglyceryl, 3-O-phospho linked Phosphatidylinositol 
(3,5)-bisphosphate (Ptdlns (3,5)Pi) was from Echelon Biosciences Inc. Dipalmitoyl 
phosphatidylinositol tris-3,4,5-phosphate ammonium salt was from Matreya Inc. Porcine 
brain L-a-phosphatidylinositol (4,5)-bisphosphate (Ptdlns(4,5)-Pz) and L-cc-
phosphatidylcholine and were from Avanti Polar Lipids, Lissamine Rhodamine B 1,2 
dihexadecanoyl sn-glycero-3-phosphatidylethanolaminetriethylammonium salt (Rh-PE) and 
FluoSN was from Molecular Probes. The protease inhibitor cocktail and Fatty acid free BSA 
were from Sigma. Bacterial Protein Extraction Reagent (B-PER) was from Pierce. 
Glutathione Sepharose 4B was from Amersham Biosciences. Lipids were prepared as 
described previously (11). 
Cloning of Stubby 
BLAST searches using IP4P Type II sequence revealed the presence of two EST 
clones, AA759168 and AI634119 encoding human Stubby (14). These two EST clones were 
obtained from the I.M.A.G.E. consortium through ATCC. The clones were sequenced from 
both directions using the flanking T7 and Universal (Ml3) vector primers. The bacterial 
expression construct for Stubby was created by PGR amplification and cloned into the 
BamHI/Smal sites of pGEX4T-l (Amersham Pharmacia Biotech). pAcGHLT-A Stubby was 
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PCR amplified using oligonucleotides 5'-
GGCCGCGTCGACTAACCATATGGGAAATCAAAGAGGAAGG-3'(sense) and 5'-
CGGGAGCTGCATGTGTCAGAG-3' (antisense), using pGEX 4T-1 Stubby as template. 
Following amplification, the fragment was TOPO-cloned into pCR 2.1-TOPO (Invitrogen) as 
per manufacturers instructions and sequenced. pCR 2.1-TOPO Stubby was digested with 
Nde-I/Not-I and ligated into pAcGHLT-A. Full length IP4P type II was cloned into 
pAcGHLT-A as follows. Using the Quick Change Site Directed Mutagenesis kit 
(SDM)(Stratagene) an Nde-I site was introduced at the 5' end of type II pCDNA3, with 
oligonucleotides Sense 5'-
GGCCGCGTCGACTAACCATATGGGAAATCAAAGAGGAAGG-3 ', and antisense-5 '-
CCTTCCTCTTTGATTTCCCATATGGTTAGTCGACGCGGCC-3 '. Nde-IP4P type II was 
subsequently digested with Nde-I and Not-I and ligated into Nde-I/Not-I digested 
pAcGHLT-A to produce type IIIP4P pAcGHLT-A. To produce IP4P IIC2, a stop mutation 
was introduced into type II using SDM and the following oligonucleotides, sense 5'-
CACAACAGACGTGCAGGGATAAAAGTGTGCCCTAGTG-3 ', antisense-5 ' -
CACTAGGGCACACTTTTATCCCTGCACGTCTGTTGTG-3 '. All constructs were 
verified by sequencing at the Iowa State sequencing center. All constructs were transfected 
into Sf-9 cells using Effectene transfection reagent (Qiagen) and with 0.1 gg of linearized 
baculoviral DNA (BD-Pharmingen) for every 0.3 gg of plasmid. The virus was amplified as 
per manufacturers instructions. All oligonucleotides were purchased from Integrated DNA 
Technologies. 
Northern Blot 
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Two Clontech multi-tissue northern blots were probed for Stubby as per the 
manufacturers instructions. The probe 5'-
CCTCAAGATCCACTTATACTCAAATTCTGGATGAGTTAGCTATG-3' was prepared 
by 5' end labeling using yATP (American Radiochemicals) and T4 polynucleotide kinase 
(Promega) according to the manufacturers protocol. 
Fluorescent Lipid Pull down Assay 
Recombinant Synaptotagmin was purified by glutathione Sepharose chromatography 
as described previously (11). Stubby and all type IIIP4P C2 domain proteins were expressed 
in Sf-9 cells as described previously (11). Each assay was read on a Titertek fluoroscan II 
(EFLAB, Finland) microtiter plate reader Ex-544nm, Em-584nm. All Ca2+ concentrations 
were determined using Fluo5N and by using the Max Chelator program 
(http://wwwstanford.edu/~cpatton.maxc.html. All graphs were created using Sigma Plot. 
Lipid Overlay Blot 
The lipid overlay was carried out as described earlier (15). The lipid blot was 
incubated overnight at 4°C with lOnM purified GST-tagged Stubby or lOnM purified GST-
tagged IP4P type IIC2. The blot was washed and incubated with an anti-GST antibody 
(Molecular Probes). The blot was washed extensively and developed using an HRP-tagged 
anti-rabbit secondary antibody, and a chemiluminescent system (Pierce). 
Ca2+ overlay assay 
The calcium overlay assay was performed as previously described (11). 
Results 
Cloning and Gene Structure of Stubby 
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The domain architecture of IP4P Type II consists of an N-terminal C2 domain and a 
C-terminal phosphatase domain. Database searches for proteins similar to IP4P type II 
revealed the presence of two human testis EST clones encoding a novel alternate splice 
variant of IP4P Type II, which we have named Stubby. Stubby consists of 131 amino acids, 
predicting a protein of molecular mass 14,739 Da (Fig.lA). The domain architecture of 
Stubby consists of an N-terminal partial C2 domain followed by a novel C-terminus 
consisting of just seven amino acids. Stubby is therefore much smaller than IP4P Type II 
(109 kDa), as it lacks the C-terminal phosphatase domain. 
Analysis of the human genomic database revealed that the gene for IP4P Type II is 
located on chromosome 4q28.1-q31.1. The gene for IP4P Type II is unusually large and is 
spread across >300 kb of DNA. The gene consists of 25 exons that can be utilized as coding 
sequence (Table 1). Stubby is formed by using exons 1 through 5 (Fig. IB). IP4P Type lia is 
formed using exons 1 though 25, excluding exons 5 and 24, while IP4P Type 11(3 is formed 
using exons 1 through 24 excluding exon 5 (Fig. IB). While the size of the exons vary from 
24 bp to 204 bp, the size of the introns vary more widely from 366 bp (intron 11) to 51,728 
bp (intron 23) (Table 1). Moreover, the IP4P Type II gene is nearly five times as large as the 
human IP4P Type I gene which is approximately 67 kb long (9). 
Northern blotting 
Northern blot analysis of the expression of Stubby is shown in (Fig 2). There is one 
primary transcript of 5.2 kilobases that is expressed in pancreas. No detectable expression of 
Stubby was seen in heart, brain placenta, lung, liver skeletal muscle or kidney. In addition, 
another multi-tissue northern blot was examined containing spleen, thymus, prostate, testis 
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ovary, small intestine, colon and peripheral blood leukocyte RNA and there was no 
detectable expression (data not shown). 
Comparative analysis of the human type IIIP4P C2 domain and Stubby 
RPS Blast database searches with the IP4P Hoc sequence and Stubby revealed the 
presence of a conserved C2-like domain with an expect value of 0.18 for the N-terminus of 
IP4P type II and 0.019 for stubby. These values are weak when compared to values of known 
C2 domains such as synaptotagmin C2A and phospholipase Côl (7xlO~40, 5x10~37). To map 
the potential ^-strands and connecting loops, a sequence alignment was performed against 
PLC 51 C2 domain (Fig 3a). The initial alignment was constructed by RPS-BLAST of each 
C2 domain followed by a manual alignment based on known C2 sequence alignments 
(11,13). Based on this homology, we hypothesize that there is sufficient sequence similarity 
between conserved hydrophobic residues located in the (3-strands and the overall alignment 
of (3-strands domain to conclude that the type IIIP4P C2 domain is a topology IIC2 domain. 
In this model, we have placed the additional sequence from Stubby as (3-strand 6. From this 
homology surprisingly, Stubby does not contain (3-strands 7 and 8 and has a shorter CBR3 
compared to the type IIC2 domain (Figure 3b). This suggests that Stubby is a unique variant 
of a C2 structure which may have different biochemical lipid and calcium binding properties. 
Type IIIP4P C2 and Stubby contain three of the Asp residues (D56, D116, D123) 
located in CBRl and CBR 3 that are known to coordinate calcium in other C2 domains such 
as phospholipase C8-1 (PLC8l)(13,16,17). In addition, Aspll9 is shifted one position from 
the PLCôl Asp residue. Surrounding the Asp residues are positively charged Lys and Arg 
residues R55, K57, K58 in CBRl and K118, K120 in CBR3. In PLCô C2 the positively 
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charged residues are involved in lipid binding (17). This suggests that type IIIP4P C2 and 
Stubby might bind lipid and calcium by a similar mechanism as typical calcium binding C2 
domains. 
Lipid Binding Analysis 
To determine whether the lipid binding property of Stubby was different from that of 
the Type II C2 domain alone, we tested its lipid binding property using a lipid overlay. As 
shown in Fig. 4A, Stubby interacted preferentially with Ptdlns(3,5)?2, Ptdlns(3,4)?2, 
Ptdlns(3,4,5)?3. This is similar to the profile found for the type IIP4P C2 domain (11). 
Interestingly, when we performed the overlay using the type IIC2 domain, it preferentially 
interacted almost exclusively with PtdIns(3,4,5)P^ (Fig 4B). This suggests that the variation 
in the type II C2 domain, Stubby and the type IIP4P C2 domains interacts with different 
biochemical signaling pathways. To confirm the lipid binding properties in a separate assay, 
lipid pull-down assays were used. In Fig 4C, both Stubby and type IIIP4P C2 domain prefer 
anionic phosphatidylinositol lipids. Stubby however, binds more lipid per microgram protein 
suggesting a higher affinity. 
Calcium overlay of type II C2 and Stubby 
Type IIP4P C2 domains have been shown to bind calcium by a 45Ca2+ overlay assay 
(11). To examine the ability of Stubby and the type IIIP4P C2 domain to bind calcium, we 
performed calcium overlays using Synaptotagmin C2A (Syt C2A), a known calcium binding 
C2 domain as a positive control and GST as a negative control (13). In Figure 5, both Stubby 
and type IIIP4P C2 domain bind calcium. Interestingly, Stubby is lacking p-strands 7 and 8 
within its structure but still binds calcium indicating that the amino acid residues necessary 
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for calcium binding are not located within the missing strands. This is consistent with the 
hypothesis that the CBRs remain intact and are involved in binding calcium. 
Effects of calcium on lipid binding of type IIC2 and Stubby 
We have shown previously that the IP4P la C2 domain exhibits a calcium dependent 
inhibition of lipid binding (11). Both IP4P type II C2 and Stubby are 37% homologous to the 
type IIP4P C2 domain (8,10). In order to evaluate the effect of calcium on lipid binding, we 
performed a lipid pull-down in the presence of calcium chelators and increasing amounts of 
calcium (Figure 6a). In agreement with type IC2 domains both the IP4P type II C2 domain 
and Stubby did not show a decrease in lipid binding in the presence of the calcium chelator 
EDTA and as calcium concentrations are increased, significant decreases in lipid binding 
occur as shown in Figure 6. The SytC2A domain was also tested using this assay as a 
positive control. Using our assay, SytC2A did not bind lipids in the presence of EDTA and 
did not show a calcium dependent inhibition consistent with data previously reported (data 
not shown)( 11,16). The effects of EGTA on lipid binding were similar to EDTA (data not 
shown). Surprisingly, similar effects were also seen for the lipid binding properties in the 
presence of Mg2+. l.OmM Mg2+ decreased binding by approximately 50 percent less than 
calcium (Figure 6b). This data suggests that the IP4P family of proteins represent a 
biochemically unique class of C2 domains whose lipid binding is inhibited by divalent 
cations. 
Effects of increasing ionic strength on lipid binding 
Calcium-dependent C2 domains such as Synaptotagmin and Piccolo are known to 
interact with the lipid head groups by primarily an electrostatic mechanism (16,18-20). This 
has also been shown for the type IIP4P C2 domain (11). There are some exceptions however 
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including cytosolic phospholipase A2 (20). To further examine the mechanism of lipid 
interaction, we used a lipid pull-down assay and increasing ionic strength. From Figure 7, 
lipid binding for both Stubby and the type II ÏÏMP C2 domain are reduced by approximately 
70% upon addition of ,5M NaCl. This is consistent with the mechanism of lipid binding of 
the type IC2 domain suggesting that the mechanism of lipid binding is maintained in the 
IP4P family of C2 domains (8,11,18,21,22). Lipid binding however did not go to 
background, this suggests that there are additional processes involved besides an electrostatic 
interactions. 
Discussion 
The IP4P family of proteins are phosphatidylinositol lipid phosphatases that catalyze 
the conversion of the lipid second messengers PtdIns(3,4)Pz to PtdIns(3)P (8). IP4P consists 
of two isoforms, type I and type II both of which are alternatively spliced. The gene for 
human IP4P Type II is enormous, spread across >320 kb of DNA. It therefore belongs to a 
rare category of genes as less than 2% of mammalian genes are >100kb in length (23). 
Comparison of this gene to the IP4P Type I gene which is located on chromosome 2ql 1.2, 
shows that the Type II gene is almost five times bigger than the Type I gene, although both 
encode 4-phosphatases of similar size (9). Interestingly, the open reading frames for both 
these genes are derived from 25 exons. Moreover, the order of exons 24 and 25, which 
encode the (3 and a splice variants respectively of IP4P, are maintained in the Type II gene as 
well. However, the hypervariable region of the IP4P Type I gene (exons 15,16 and 17), 
which gives rise to the Type loci, «2 and % splice forms are missing in the Type II gene (9). 
Conversely, exon 5 of the IP4P Type II gene which gives rise to Stubby, is missing in the 
Type I gene. 
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Although the original EST clone for Stubby was from human testis, Northern blot 
analysis detected a 5.3-kilobase transcript of Stubby solely in pancreas. IP4P type II was 
previously shown by Northern blot to be primarily expressed in heart and skeletal muscle 
with lower abundance transcripts been located in brain, placenta, and pancreas respectively 
(10). The difference in expression profiles indicates that Stubby may have unique tissue 
specific functions. 
The analysis of the sequences of PLC ôl C2 domain suggests that both Stubby and 
the type IIIP4P C2 domains are similar to topology IIC2 domains. Other proteins that 
contain topology IIC2 domains include PI3-kinase class IB (PI3Ky) and phospholipase A2 
(24,25). Stubby is an unusual protein as it consists of only a partial C2 domain lacking p-
strands seven and eight. To our knowledge, it is the first member of the C2 domain family 
that consists of only a single C2 domain with very little additional sequence. Both Stubby 
and type IIIP4P C2 domains can interact with lipids however, suggesting that the mechanism 
of interaction does not involve strands 7 and 8. The structural variation may influence lipid 
specificity as lipid overlay blot showed a dramatic preference, however using a lipid pull­
down assay a broader interaction was indicated under these conditions. They both also 
interact with the lipids head groups by a similar mechanism as evidenced by the effects of 
increasing ionic strength. 
Calcium overlays indicated that both Stubby and the type IIC2 domain bind calcium. 
Interestingly, both the type IIC2 domain and Stubby showed a calcium dependent inhibition 
of lipid binding. Synaptotagmin C2A and other calcium dependent C2 domain containing 
proteins do not have this property and have been shown to bind lipids in the presence of 
calcium (16,26). This unusual property was previously shown to be a feature of the type I 
88 
IP4P C2 domain. Moreover both type II and Stubby are shown to be inhibited by Mg2+ to a 
lesser degree (Figure 6b)(data not shown). Combined, this suggests that the IP4P family of 
proteins is uniquely regulated by divalent cations. 
PtdIns(3,4,5)P3 and PtdIns(3,4)P^ are lipids frequently found in vesicular membranes 
and have been implicated in processes such as phagosomal maturation and the oxidative 
burst (1,6,27,28). To complete the hydrolysis of their substrates, IP4Ps must be able to 
interact with membranes. Other phosphatases such as the Ptdlns 3-phosphatase PTEN have 
been shown to contain C2 domains that are involved in coordination of their lipid substrate 
for activity (29,30). Calcium has already been shown to negatively regulate type IIP4P 
activity in platelets by the calcium-dependent protease calpain (5). Calcium inhibition of 
membrane association could potentially augment the inhibition of this enzyme under 
increased calcium conditions. The existence of Stubby, a spliceoform of type IIIP4P, implies 
that the C2 domain can function independently. Possible functions of this C2-like protein 
could be to interact with an effector to modulate the ability of type IIIP4P or their signaling 
partners to function. It also could influence the recruitment of other associated proteins to the 
membrane. 
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Figure Legends 
Fig. 1: Structure of Stubby. A. Nucleic acid and amino acid sequence of Stubby. The 
alternate spliced region is boxed. B. Chromosome organization of IP4P Type II. Schematic of 
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the gene structure of human IP4P Type II with 25 exons. The alternate splice variant, Stubby 
is formed using exon 5. 
Fig. 2: Northern Analysis of Stubby mRNA expression. A human Multi-tissue Northern blot 
from Clontech was probed for the presence of Stubby in the issues indicated. 
Fig. 3: Secondary Structure of Stubby A. Sequence alignment of Phospholipase ôl C2, type 
IIIP4P C2 and Stubby, p strands for each topology are shown below the sequences. Calcium 
and lipid binding loops (CBR) are shown below in bold. Residues that interact with calcium 
in PLC 61 and their homologous residues in type IIIP4P C2 and Stubby are shown in bold. 
Conserved residues are shaded in gray. B. Block diagram of |3-strands in Stubby (shaded 
white) plus p-strands 7 and 8 that are not found in Stubby (Shaded gray). 
Fig. 4: Lipid binding properties of IP4P Type II and Stubby. Phospholipid overlay blots 
using (A) Purified GST-tagged Stubby or (B) purified GST-tagged IP4P Type II C2 domain. 
Binding was detected using an anti-GST antibody coupled with a chemiluminescent 
detection system. C. Fluorescent lipid pull-down assay demonstrating lipid binding properties 
of Stubby and type IIIP4P C2 domains. GST-type IIIP4P C2 (black bars), Stubby (gray 
bars) or GST beads (white bars). The data are mean with S.E. using three independent 
experiments. 
Fig. 5: Calcium binding of type IIIP4P C2 and Stubby. Overlay assay of 45Ca2+ binding of 
GST-type IIIP4P C2 and Stubby compared to GST and GST-Synaptotagmin C2A. 2|ig of 
each protein was spotted on a nitrocellulose membrane and incubated with 45Ca2+. Proteins 
were quantified using Coomassie blue staining with a 10% SDS-PAGE gel. 
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Fig. 6: Effects of EDTA and divalent cations on type IIIP4P C2 and Stubby lipid binding. A. 
Effects of increasing calcium on lipid binding. IP4P type IIC2 binding shown in black bars, 
Stubby is shown in gray and GST binding shown in white. B. Effects of increasing 
magnesium concentrations on lipid binding. Type IIIP4P C2 binding shown in black bars, 
Stubby is shown in gray bars. Calcium concentrations were verified using Max Chelator and 
Fluo 5N. The data are mean with S.E. using three independent experiments. 
Fig. 7: Effects of ionic strength on Stubby and type IIIP4P C2 binding to phospholipid 
vesicles. Lipid vesicles were prepared as described previously with increasing amounts of 
NaCl as shown. Type IIIP4P C2 binding shown in black bars, Stubby is shown in gray and 
GST binding shown in white. The data are mean with S.E. using three independent 
experiments. 
Table 1: Gene structure of human IP4P Type II. Table showing the intron-exon boundaries 
of IP4P Type II gene. A. 5' exon boundary is defined as the start ATG; B. alternate spliced 
exons; C. 5' intron boundary is not determined (ND) and is defined by the stop codon. 
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Figures 
Figure 1 
A 1 atggaaattaaagaggaaggggcatcagaagaagggcagcactttcttcctacagcccag 
M E I K E E G A S E E G Q H F L P T A Q 2 0  
61 gccaatgatcccggggactgtcagttcacaagtatccagaagactccaaatgaaccgcag 
A N D P G D C Q F T S  I Q K T P N E P Q 4 0  
121 ttggaattcatccttgcatgcaaggatctcgtggctcctgtccgtgatcgtaaactgaat 
L E F I L A C K D L V A P V R D R K L N 6 0  
181 acactggtgcagatctccgtaatccaccccgtggagcagagtctgacaagatactccagc 
T L V Q I S V I H P V E Q S L T R Y S S 8 0  
241 accgaaattgtggagggaacaagggacccactgtttttgactggtgtcacattcccatct 
T E I V E G T R D P L F L T G V T F P S  1 0 0  
301 gagtatcccatctatgaggagaccaaaataaaactaacagtctatgatgtcaaggataag 
E Y P  I Y E E T K I  K L T V Y D V K D K 1 2 0  
361 tctcatqacaccataqctaactcatccaqaatttqa 396 
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Figure 4 
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Table 1 
Organization of the Human Inositol Polyphosphate 4-Phosphatese Type II Gene 
Exon Exon boundary Exon Intron Intron boundary Intron 
no. 5' 3' length no. 5' 3' length 
1° ATGGAA TCACAA 91 1 gtaagtatg tatttatag 1951 
2 GTATCC TCCTTG 45 2 gtaagaaat cgttgccag 23848 
3 CATGCA GTGGAG 119 3 gtgagatgc ctgttacag 2 1 5 1  
4 GGAACA GACACC 1 1 7  4 gtaagtact cttcccaag 18821 
5b ATAGCT ATTTGA 24 5 ND" tctccacag -
6 GTTCGA GTTGGG 51 6 gtaagtgaa tattttcag 9174 
7 CGAAGT CCTGAG 80 7 gtgggtctc Mgttgcag 34683 
8 AACTTC CAAAAG 1 1 2  8 gtaggatct ttttcctag 10098 
9 TGTGCC ATTCAG 73 9 gtatgtaac tttttccag 22480 
10 TGTTAA GTGCAG 148 10 gtaagagaa tcttaacag 28837 
il AAACCA AAACAG 1 3 1  11 gtgtggaag ttccatcag 366 
12 GGTCCT TGAAAG 105 12 gtatcataa ctactccag 15229 
13 ATGCTC AAGAAA 109 13 gtaagtaaa ttgttgcag 19277 
14 TACCGG GAAAAA 178 14 gtaagatcc tctttccag 13070 
15 ACAGAG GAGTGG 204 15 gtaagtctc ttttttcag 14361 
16 GACAGG CAAGAG 157 16 gtaagaaat ttcccccag 21079 
17 AGGACT CAAGCA 173 17 gtaggtgcc ttttttcag 1 1 7 2  
18 CTTGCT CATACA 124 18 gtgagtatt attgtttag 1046 
19 GCGATG AAGACG 118 19 gtaagcagt cttctttag 9445 
20 AGAACA TGAAAG 141 20 gtaagcttt tgtttgtag 4351 
21 GTTTGG CTGATT 98 21 gtaagtatg ccccttcag 21836 
22 ATATTT GCAACG 1 1 3  22 gtaagcact atgttacag 3958 
23 ATTTGC GAGAAG 155 23 gtatctcac atttaacag 51728 
24^ CAGACA CAATAA 174 24 ND' tttcaccag -
25*" AGAAGG ACCTAA 1 3 3  25 ND= 
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CHAPTER 5. GENERAL CONCLUSIONS 
Summary 
The primary focus of the Norris lab is the study of Inositol polyphosphate 4-
phosphatases (IP4P). IP4Ps are lipid phosphatases that remove the 4-position phosphate from 
the lipid second messengers phosphatidylinositol 3,4 bis-phosphate converting it to 
phosphatidylinositol 3 phosphate (1). There are two families of IP4Ps that are 37% 
homologous to each other denoted type I and type II. IP4P are lipid phosphatases, therefore 
they must be able to get to membranes to have access to their substrate (2). Currently the 
mechanism of membrane recruitment and binding is unknown. 
So, is there a domain within the IP4P family that is capable of binding lipids in 
addition to the active site? To answer this question, various lipid binding assays have been 
used to identify a C2 domain in both type I and type II IP4Ps that binds calcium and 
phosphatidylinositols. In addition, both calcium and magnesium inhibit the ability of IP4P C2 
domains to bind lipids. 
Previously several different isoforms of both type I and type IIIP4P had been 
identified. These included the (3-spliceoforms of both type I and II that contained a 
hydrophobic tail instead of a hydrophilic one and a novel deletion spliceoform found in brain 
tissue that was approximately lkDa smaller than type la characterized in mouse brain tissue 
called type Ida (3). When examining the gel, there was an additional band running higher 
than type la on an SDS PAGE gel when lysates from Jurkat T-cells were run. So is this an 
additional spliceoform or is it a post-translational modification of type la? In answering this 
question a novel spliceoform was identified that is the predominant IP4P not only in 
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lymphocytes but in platelets and neutrophils as well. IP4P type lag is an 1 lOkDa splice 
variant of type I IP4P's that contains an additional 40 amino acids creating a PEST region. 
This protein could have specialized roles in immune related functions. 
The second is a short spliceoform of type IIIP4P denoted Stubby that only contains a 
lipid binding C2 domain. The C2 domain of Stubby is not complete however, by sequence 
homology only (3-strands 1-6 however, all three calcium-binding loops are present. With this 
in mind, can Stubby still interact with lipids and calcium even though it does not contain a 
full C2 domain? Comparison of the lipid binding properties of Stubby and the type IIC2 
domain revealed different substrate specificity. In a lipid overlay the IP4P type IC2 domain 
and Stubby prefer to bind phosphatidylinositol 3,5-bisphosphate whereas the type IIC2 
domain prefers phosphatidylinositol 3,4,5-trisphosphate. This suggests that different forms of 
IP4's are localized to different places in the cell. In addition, the fact that Stubby is still able 
to bind calcium and lipids gives greater insight on the mechanism of IP4P C2 domain 
function. 
Future Study 
An important part of research is that when questions begin to be answered, these 
answers stimulate new questions that can be asked. This research opens new doorways for 
the study of biochemical and structural regulation of EP4P family members. 
For starters, preliminary evidence exists for the presence of the PEST sequence 
having an effect on calpain mediated proteolytic susceptibility of the longer isoform. It would 
be interesting to examine different permtations of the three type la isoforms in the context of 
the removal of part or all of the PEST domains. Would the proteins still get cleaved? Where 
are they cleaved by calpains, we have preliminary evidence that at least two of the sites of 
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calpain cleavage are near the variable region and hence near PEST sequences. Currently 
there is only evidence that type I013 is cleaved in vivo, are type la and type Ia% also cleaved in 
vivo? In fact are type II IP4Ps also cleaved by calpains? They do not have a PEST homology 
domain. 
Type IIP4P has been implicated in the regulation of the oxidative burst in neutrophils 
by the production of PtdIns(3)P (5). All of this work was performed in vitro however. There 
are now systems that can use the ability of transfections to examine individual components 
during the production of the reactive oxidative burst. One of these systems is the COSphox 
system. This system uses COS cells that have been stably transfected with the components of 
the NADPH oxidase (p91, p22, p47phox, p67 phox, Rac2) (6). Upon stimulation the cytosolic 
components will translocates to the membrane and produce superoxides. This system is ideal 
for the examination of the role of IP4P in the production of the oxidative burst. To date 
numerous mutants including the catalytically inactive CS and C2 domain mutants have been 
created that can be examined in this system. Is type IIIP4P capable of stimulating superoxide 
production. In recent years other tissues have been shown to express homologs of the phox 
proteins (7,8). It is unknown if type I or type II is the predominant form in these tissues. 
Also, in vitro activity has not been demonstrated for type 1(3 IP4P. Can this activity be 
determined using the COS phox system or perhaps examination of lysates prepared from 
IP4P Ip infected Sf-9 cells? 
Now that there is evidence of a C2 domain on the N-terminus of IP4Ps, does it get 
recruited to the membrane, where does it go, and does it react to stimuli? Using GFP tagged 
constructs, preliminary evidence suggests that the type IC2 domain could be localized at 
vesicular bodies. Further research needs to be completed examining this in the context of 
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colocalization with other proteins known to localize to endosomes or lysosomes such as 
EEA1 or LAMP1. 
The role of EP4P in phagocytosis can also be examined. Using the RAW cell 
phagocytic system, different GFP tagged versions of IP4P can be examined under the context 
of phagosomal fusion (9). Does the inactive mutant block this process? 
The presence of C2 domains in both type I and II IP4Ps gives rise to some interesting 
questions. First, if a mutation of the C2 domains blocks lipid binding what are its effects on 
overall protein activity? Could the C2 domain also play a role in orientation of the active 
site? Second what is the role of CBR3 in lipid binding. Although there is little difference in 
lipid specificity using the pull-down system there is a clear difference using the overlay 
system. Is this difference due to the longer CBR3 in type II when compared to Stubby and 
type IC2 domains? The crystal structures of many C2 domains have been solved; to date 
IP4Ps are the first C2 domains that are negatively regulated by calcium. Can crystal 
structures be obtained for IP4P family C2 domains? These structures would provide insight 
into the mechanism of lipid binding. They would also verify that the overall predicted 
structure of the (3-strands and CBRs are correct. Also can calcium coordination be 
determined from the crystal structures? This could help answer why calcium negatively 
regulates lipid binding. It would also help answer if amino acids in the longer CBR3 loop 
found in type IIC2 domains are properly coordinated to interact with lipid head groups. 
From the data obtained from the crystals, additional mutations can be made and their effects 
on lipid binding evaluated. How do the CBR loops of IP4P interact with membranes, do they 
penetrate the membrane or is the interaction primarily due to surface interactions? NaCl does 
not completely eliminate lipid-binding, this suggests that there is some association with the 
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hydrophobic tails within the membrane. Using techniques such as Surface Plasmon 
Resonance this question can be addressed. In addition, what are the dissociation constants for 
lipid binding and for calcium binding? Does calcium interact with IP4P C2 domains in the 
physiological range? 
Stubby is a natural spliceoform of type IIIP4P that only consists of the first 2/3 of the 
C2 domain. What is the role of Stubby? Could Stubby be involved as an adaptor protein 
which can bind other proteins once it is on the membrane? There is preliminary evidence that 
Stubby will associate with the type IIC2 domain. This could give rise to the association of 
protein complexes using Stubby or the type IIIP4P. Or is Stubby involved in the regulation 
of type II lipid binding. An interesting experiment would be to determine using a lipid 
competition assay if Stubby could supplant the type IIC2 domain in binding lipids. Also 
where in a cell is Stubby located? 
Biological significance 
The discovery of two new spliceoforms within the IP4P family provides additional 
tools for the understanding of how IP4P tissue specificity can lead to differential regulation. 
The first spliceoform (type la 3) is present primarily in hematopoietic cells. The fact that it 
contains an additional PEST element provides clues to how it is regulated. Gaining a better 
understanding of how type IIP4P family members are proteolytically regulated will provide 
clues to their overall function within the cell. 
Second and most importantly is the significance of a lipid-binding domain within the 
IP4P family. Although all of this work is in vitro, the biological significance of the findings 
from this thesis is several fold. Reports have shown that regulation of IP4P occurs in many 
cellular processes. These range from platelet activation to production of superoxides in 
neutrophils, including development of Purkinje cells in the brain (13,14). For the first time a 
lipid-binding domain has been characterized that could recruit IP4Ps to their substrates. The 
lipid binding property of this domain is negatively regulated by calcium. This research 
provides clues on how IP4P family members bind to membranes and how they are regulated 
within the cell. With this knowledge, a better understanding of cellular processes such as 
phagocytosis and the production of reactive oxidative intermediates will be gained. The 
production of ROI's is known to cause damage during diseases such as heart attacks and 
strokes (15). In fact, superoxide has been shown to be produced even in platelets (16). In 
addition, inhibition of calpain proteases has been shown to decrease damage during 
ischemia-reperfusion injury (17-19). Recall that mutant alleles of IP4P are more resistant to 
oxidative stress in a C. elegans model (Walker, J, Peterson, K, Norris, F.A.-unpublished 
data). The involvement of IP4P in oxidative stress resistance could be regulated by calpain. 
IP4P could be an integral protein involved in the regulation of such processes, gaining better 
insight in the regulation of IP4P will provide possible pathways of treatment in the future. 
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